image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
ada4f7575b66134ce2a1a3f29b9058d80dbdb27102a31f6b38f528675173d8bd.png | complex | <table><tr><td>Serum parameter</td><td colspan="3">Case</td><td colspan="3">Control</td><td>Between groups comparison (<i>P</i>-value)<sup>a</sup></td></tr><tr><td></td><td><i>N</i></td><td>Baseline (mean ± SD</td><td>Follow-up (mean ± SD)</td><td><i>N</i></td><td>Baseline (mean ± SD)</td><td>Follow-up (mean ± SD)</td><td></td></tr><tr><td>FT3 (pmol/L)</td><td>103</td><td>4.34 ± 0.6</td><td>4.57 ± 0.2<sup>b</sup></td><td>412</td><td>4.85 ± 0.7</td><td>4.30 ± 0.5<sup>b</sup></td><td><0.001</td></tr><tr><td>FT4 (pmol/L)</td><td>103</td><td>9.06 ± 1.1</td><td>13.4 ± 1.0<sup>b</sup></td><td>412</td><td>14.7 ± 2.8</td><td>13.5 ± 1.0<sup>b</sup></td><td><0.001</td></tr><tr><td>Anti-TPO (kU/L)</td><td>103</td><td>162.8 ± 120</td><td>43.4 ± 116<sup>b</sup></td><td>412</td><td>21.5 ± 54.8</td><td>18.8 ± 26.7</td><td><0.001</td></tr><tr><td>Anti-TG (kU/L)</td><td>103</td><td>51.8 ± 33.7</td><td>17.6 ± 27.2<sup>b</sup></td><td>412</td><td>32.0 ± 61.3</td><td>14.5 ± 30.7<sup>b</sup></td><td>0.05</td></tr><tr><td>TSH (mlU/L)</td><td>103</td><td>5.97 ± 4.2</td><td>2.50 ± 1.1<sup>b</sup></td><td>412</td><td>1.78 ± 0.7</td><td>1.98 ± 0.6<sup>b</sup></td><td><0.001</td></tr><tr><td>TG (μg/L)</td><td>31</td><td>43.1 ± 39.4</td><td>25.6 ± 4.0<sup>b</sup></td><td>244</td><td>28.2 ± 26.3</td><td>25.4 ± 5.9</td><td>0.003</td></tr><tr><td>hs-CRP (mg/L)</td><td>103</td><td>2.05 ± 2.2</td><td>2.52 ± 1.4</td><td>412</td><td>2.35 ± 3.1</td><td>2.41 ± 1.9</td><td>0.2</td></tr><tr><td>25(OH)D (nmol/L)</td><td>103</td><td>68 ± 32</td><td>110 ± 14<sup>b</sup></td><td>412</td><td>82 ± 34</td><td>110 ± 27<sup>b</sup></td><td>0.001</td></tr><tr><td>Vitamin D dose (IU/day)</td><td>103</td><td>1243 ± 2606</td><td>3517 ± 2620<sup>b</sup></td><td>412</td><td>1824 ± 2770</td><td>4150 ± 3321<sup>b</sup></td><td>0.9</td></tr></table> |
d9460e710e88ae95a39cc39139357cd02cd33446e3530709ecd18df84276583e.png | complex | <table><tr><td colspan="2">Food Ingestion Rate (F<sub>IR</sub>) Limitation (g/day)</td><td>As</td><td>Cd</td><td>Cr</td><td>Cu</td><td>Pb</td><td>Zn</td></tr><tr><td colspan="8">Based on target hazard quotients (THQ)</td></tr><tr><td rowspan="2">Cultured fish</td><td>Muscle</td><td>/</td><td>/</td><td>339,296</td><td>3027</td><td>1253</td><td>1018</td></tr><tr><td>Mixed tissues</td><td>/</td><td>5162</td><td>526,225</td><td>1057</td><td>2227</td><td>452</td></tr><tr><td rowspan="2">Wild fish</td><td>Muscle</td><td>/</td><td>10,707</td><td>49,497</td><td>6168</td><td>4894</td><td>1183</td></tr><tr><td>Mixed tissues</td><td>1529</td><td>1352</td><td>135,527</td><td>1506</td><td>1420</td><td>396</td></tr><tr><td colspan="8">Based on carcinogenic risk (CR)</td></tr><tr><td rowspan="2">Cultured fish</td><td>Muscle</td><td>/</td><td>/</td><td>/</td><td>/</td><td>3684</td><td>/</td></tr><tr><td>Mixed tissues</td><td>/</td><td>/</td><td>/</td><td>/</td><td>6550</td><td>/</td></tr><tr><td rowspan="2">Wild fish</td><td>Muscle</td><td>/</td><td>/</td><td>/</td><td>/</td><td>14,396</td><td>/</td></tr><tr><td>Mixed tissues</td><td>340</td><td>/</td><td>/</td><td>/</td><td>4178</td><td>/</td></tr><tr><td colspan="8">Based on estimated weekly intake (EWI)</td></tr><tr><td rowspan="2">Cultured fish</td><td>Muscle</td><td>/</td><td>/</td><td>465</td><td>36,284</td><td>1072</td><td>3253</td></tr><tr><td>Mixed tissues</td><td>/</td><td>4950</td><td>721</td><td>12,673</td><td>1907</td><td>1445</td></tr><tr><td rowspan="2">Wild fish</td><td>Muscle</td><td>/</td><td>10,267</td><td>68</td><td>73,932</td><td>4190</td><td>3780</td></tr><tr><td>Mixed tissues</td><td>10,475</td><td>1297</td><td>186</td><td>18,052</td><td>1216</td><td>1265</td></tr></table> |
0d19c0c71ee6b79107645f8022525b1055b32647e180706d0fc3d492c25ddf35.png | complex | <table><tr><td>Strategy in small animal models</td><td>Advantages</td><td>Disadvantages</td></tr><tr><td rowspan="4">Knockout mice</td><td>Susceptible to a wide range of clinical isolates of viruses</td><td>Cannot study immune responses properly due to abnormal innate immunity</td></tr><tr><td>Can study pathogenesis of a new pathogen rapidly</td><td>Some viruses may not cause disease in knockout mice</td></tr><tr><td></td><td>Cannot test drugs and vaccines effectively</td></tr><tr><td></td><td>Can be age-sensitive: older mice may lose their susceptibility to the pathogen</td></tr><tr><td rowspan="3">Virus adaptation to host via sequential passaging</td><td>Can cause uniform lethality</td><td>Not always successful in creating a lethal variant</td></tr><tr><td>Good for screening drugs and vaccines</td><td>Can be time consuming to create a lethal variant</td></tr><tr><td>Wild-type mice are widely available</td><td>Not clinical isolate of virus and thus may harbour important differences in pathogenesis</td></tr><tr><td rowspan="2">Transduction with adenoviral vectors encoding the entry receptor to confer sensitivity</td><td>Useful when no other known small animal models exist (i.e., MERS)</td><td>Need to know the identity of the receptor</td></tr><tr><td>Can test with clinical isolate of virus</td><td>Time consuming to create the recombinant adenovirus</td></tr></table> |
d8ecbcf023f8bde3b577d6ac42a2ff56009bc4d298615965bca317e971eb8d94.png | simple | <table><tr><td>Patient nr</td><td>Gender</td><td>Age of onset</td><td>PMD (hours)</td><td>Disease duration (years)</td><td>ALS type</td></tr><tr><td>1</td><td>F</td><td>66</td><td>6</td><td>4.5</td><td>Sporadic ALS</td></tr><tr><td>2</td><td>F</td><td>61</td><td>Unknown</td><td>1</td><td>Sporadic ALS</td></tr><tr><td>3</td><td>M</td><td>56</td><td>10</td><td>3.5</td><td>Sporadic ALS</td></tr><tr><td>4</td><td>F</td><td>80</td><td>Unknown</td><td>2</td><td>Sporadic ALS</td></tr><tr><td>5</td><td>M</td><td>68</td><td>Unknown</td><td>3.5</td><td>Familial ALS<sup>a</sup></td></tr><tr><td>6</td><td>F</td><td>57</td><td>9.5</td><td>3.5</td><td>Sporadic ALS</td></tr><tr><td>7</td><td>M</td><td>62</td><td>Unknown</td><td>4</td><td>Sporadic ALS</td></tr><tr><td>8</td><td>M</td><td>72</td><td>Unknown</td><td>X</td><td>Sporadic ALS</td></tr><tr><td>9</td><td>M</td><td>68</td><td>Unknown</td><td>3.5</td><td>Sporadic ALS</td></tr><tr><td>10</td><td>M</td><td>54</td><td>Unknown</td><td>1.5</td><td>Familial ALS<sup>a</sup></td></tr><tr><td>11</td><td>F</td><td>58</td><td>10–11</td><td>2</td><td>Sporadic ALS</td></tr></table> |
4c623d0114d9ad20eb34bae552b7219b40d16f28ec90cbbabd0e93c0535a3eed.png | complex | <table><tr><td>Characteristic</td><td colspan="2">LTFU</td><td colspan="2">Viral rebound<sup>a</sup></td></tr><tr><td> </td><td>Univariate HR (95% CI)</td><td>aHR (95% CI) (n = 3106)</td><td>Univariate HR (95% CI)</td><td>aHR (95% CI) (n = 3106)</td></tr><tr><td>Age at AC enrolment (years)</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> 16-24</td><td>2.16 (1.06-4.40)</td><td>2.41 (1.10-5.23)</td><td>1.60 (0.68-3.76)</td><td>1.52 (0.59-3.95)</td></tr><tr><td> 25-34</td><td>1.37 (0.93-2.00)</td><td>1.55 (1.03-2.33)</td><td>1.64 (1.11-2.41)</td><td>1.74 (1.17-2.59)</td></tr><tr><td> 35-44</td><td>1.0 (ref)</td><td>1.0 (ref)</td><td>1.0 (ref)</td><td>1.0 (ref)</td></tr><tr><td> ≥ 45</td><td>0.99 (0.58-1.69)</td><td>1.04 (0.60-1.82)</td><td>0.70 (0.37-1.32)</td><td>0.69 (0.36-1.31)</td></tr><tr><td>Sex</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Male</td><td>0.99 (0.68-1.44)</td><td>1.13 (0.77-1.68)</td><td>0.77 (0.51-1.15)</td><td>0.94 (0.62-1.43)</td></tr><tr><td>Duration on ART at AC</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> enrolment (years)</td><td>0.97 (0.88-1.07)</td><td>0.98 (0.89-1.09)</td><td>1.07 (0.98-1.17)</td><td>1.12 (1.03-1.23)</td></tr><tr><td>Ever sent a buddy</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Yes</td><td>0.75 (0.52-1.07)</td><td>0.79 (0.55-1.14)</td><td>0.63 (0.43-0.92)</td><td>0.63 (0.43-0.93)</td></tr><tr><td>Number of clubs at facility/1000 patients</td><td>1.01 (0.93-1.09)</td><td>1.02 (0.93-1.11)</td><td>0.96 (0.89-1.03)</td><td>0.94 (0.87-1.02)</td></tr><tr><td>Number of patients on ART in facility/1000</td><td>1.34 (1.13-1.59)</td><td>1.32 (1.11-1.58)</td><td>0.99 (0.81-1.20)</td><td>0.97 (0.79-1.18)</td></tr></table> |
e86f63ea8c72c1f4541c024818ed609aa67903b400b7b04cfb29a329d228465e.png | simple | <table><tr><td>Protein</td><td># Unique peptides</td><td>% Coverage</td></tr><tr><td>CUL4A</td><td>6</td><td>10.2</td></tr><tr><td>DDB1</td><td>4</td><td>7.9</td></tr><tr><td>TOP2A</td><td>14</td><td>10.1</td></tr><tr><td>MCM6</td><td>1</td><td>1.8</td></tr><tr><td>MCM7</td><td>1</td><td>1.2</td></tr></table> |
2d23fb914ecec208ee60f013e7529234866b95b92709f99c7ba30379a42ae78d.png | complex | <table><tr><td></td><td>Type I error</td><td colspan="4">Power</td><td colspan="5">Coverage probability</td></tr><tr><td></td><td>IF = 0</td><td>IF = 0.3</td><td>IF = 0.45</td><td>IF = 0.6</td><td>IF = 1</td><td>IF = 0</td><td>IF = 0.3</td><td>IF = 0.45</td><td>IF = 0.6</td><td>IF = 1</td></tr><tr><td></td><td colspan="10">All-cause mortality outcome (median (τ<sup>2</sup>) = 0.02)</td></tr><tr><td>IVDL</td><td>0.05</td><td>0.14</td><td>0.23</td><td>0.38</td><td>0.75</td><td>0.95</td><td>0.97</td><td>0.99</td><td>0.98</td><td>0.95</td></tr><tr><td>KHDL</td><td>0.11</td><td>0.21</td><td>0.32</td><td>0.46</td><td>0.78</td><td>0.89</td><td>0.94</td><td>0.93</td><td>0.92</td><td>0.90</td></tr><tr><td></td><td colspan="10">Subjective outcome (median (τ<sup>2</sup>) = 0.11)</td></tr><tr><td>IVDL</td><td>0.07</td><td>0.14</td><td>0.23</td><td>0.34</td><td>0.63</td><td>0.94</td><td>0.96</td><td>0.96</td><td>0.97</td><td>0.95</td></tr><tr><td>KHDL</td><td>0.12</td><td>0.20</td><td>0.29</td><td>0.41</td><td>0.65</td><td>0.88</td><td>0.93</td><td>0.93</td><td>0.92</td><td>0.91</td></tr></table> |
48f184553fa601f1d9471a5dd065305dc21be30a12ce0adf3ebf67fff273f7a1.png | complex | <table><tr><td>Pollutant</td><td>Lag</td><td>All months</td><td>Warm months</td><td>Cold months</td></tr><tr><td rowspan="5">CO</td><td>0</td><td>0.99 (0.96–1.02)</td><td>1.07 (0.97–1.17)</td><td>0.98 (0.95–1.01)</td></tr><tr><td>1</td><td>0.99 (0.96–1.01)</td><td>1.13 (1.02–1.25)*</td><td>0.97 (0.94–1.00)</td></tr><tr><td>2</td><td>1.02 (0.99–1.04)</td><td>1.17 (1.06–1.29)*</td><td>1.00 (0.97–1.03)</td></tr><tr><td>3</td><td>1.00 (0.97–1.03)</td><td>1.08 (0.97–1.19)</td><td>0.99 (0.96–1.02)</td></tr><tr><td>4</td><td>1.01 (0.98–1.04)</td><td>1.11 (1.01–1.23)*</td><td>1.00 (0.97–1.03)</td></tr><tr><td rowspan="5">NO<sub>2</sub></td><td>0</td><td>0.99 (0.94–1.03)</td><td>0.97 (0.88–1.08)</td><td>0.99 (0.94–1.04)</td></tr><tr><td>1</td><td>0.97 (0.93–1.01)</td><td>0.99 (0.89–1.10)</td><td>0.96 (0.92–1.01)</td></tr><tr><td>2</td><td>1.03 (0.99–1.08)</td><td>1.04 (0.94–1.15)</td><td>1.03 (0.98–1.08)</td></tr><tr><td>3</td><td>1.00 (0.96–1.04)</td><td>1.04 (0.94–1.16)</td><td>0.99 (0.94–1.04)</td></tr><tr><td>4</td><td>1.00 (0.95–1.04)</td><td>1.04 (0.94–1.16)</td><td>0.99 (0.94–1.04)</td></tr><tr><td rowspan="5">SO<sub>2</sub></td><td>0</td><td>0.98 (0.95–1.02)</td><td>0.97 (0.91–1.03)</td><td>0.99 (0.94–1.03)</td></tr><tr><td>1</td><td>0.98 (0.95–1.02)</td><td>0.99 (0.93–1.05)</td><td>0.98 (0.94–1.02)</td></tr><tr><td>2</td><td>0.98 (0.95–1.01)</td><td>0.97 (0.91–1.03)</td><td>0.98 (0.94–1.02)</td></tr><tr><td>3</td><td>0.98 (0.95–1.02)</td><td>1.04 (0.98–1.11)</td><td>0.95 (0.92–0.99)*</td></tr><tr><td>4</td><td>1.01 (0.97–1.04)</td><td>1.04 (0.98–1.11)</td><td>0.99 (0.95–1.03)</td></tr><tr><td rowspan="5">O<sub>3</sub></td><td>0</td><td>1.09 (1.03–1.16)*</td><td>1.11 (1.00–1.24)*</td><td>1.09 (1.01–1.18)*</td></tr><tr><td>1</td><td>1.06 (0.99–1.12)</td><td>0.97 (0.87–1.08)</td><td>1.12 (1.03–1.21)*</td></tr><tr><td>2</td><td>0.99 (0.93–1.05)</td><td>0.97 (0.87–1.08)</td><td>1.02 (0.94–1.10)</td></tr><tr><td>3</td><td>1.05 (0.99–1.12)</td><td>1.05 (0.94–1.17)</td><td>1.07 (0.99–1.15)</td></tr><tr><td>4</td><td>1.02 (0.96–1.09)</td><td>0.98 (0.88–1.09)</td><td>1.06 (0.98–1.14)</td></tr><tr><td rowspan="5">PM<sub>10</sub></td><td>0</td><td>1.02 (0.97–1.06)</td><td>1.04 (0.97–1.10)</td><td>1.00 (0.95–1.06)</td></tr><tr><td>1</td><td>0.98 (0.95–1.03)</td><td>1.04 (0.97–1.11)</td><td>0.95 (0.90–1.01)</td></tr><tr><td>2</td><td>1.01 (0.97–1.05)</td><td>1.05 (0.98–1.12)</td><td>1.00 (0.95–1.05)</td></tr><tr><td>3</td><td>0.98 (0.95–1.02)</td><td>1.04 (0.97–1.11)</td><td>0.97 (0.92–1.02)</td></tr><tr><td>4</td><td>1.00 (0.96–1.04)</td><td>1.03 (0.97–1.10)</td><td>1.00 (0.95–1.05)</td></tr><tr><td rowspan="5">PM<sub>2.5</sub></td><td>0</td><td>1.03 (0.98–1.08)</td><td>1.04 (0.97–1.12)</td><td>1.04 (0.97–1.11)</td></tr><tr><td>1</td><td>1.00 (0.95–1.05)</td><td>1.07 (0.99–1.15)</td><td>0.98 (0.91–1.04)</td></tr><tr><td>2</td><td>0.97 (0.93–1.02)</td><td>1.01 (0.93–1.10)</td><td>0.97 (0.91–1.03)</td></tr><tr><td>3</td><td>0.95 (0.90–0.99)*</td><td>0.96 (0.88–1.05)</td><td>0.95 (0.89–1.01)</td></tr><tr><td>4</td><td>0.98 (0.93–1.02)</td><td>1.00 (0.93–1.08)</td><td>0.96 (0.90–1.03)</td></tr></table> |
1eb4af8b63d986b48dfc180dda9da93da6711ea59eff2106a145017348c52b0d.png | simple | <table><tr><td>Parameters</td><td> 0 days (mean ± SD)</td><td> 30 days (mean ± SD)</td><td> 60 days (mean ± SD)</td><td><i>F</i> value</td><td><i>P</i> value</td></tr><tr><td>Malondialdehyde (MDA) (nmoL/mL)</td><td>3.78 ± 0.24</td><td>3.11 ± 0.25</td><td>2.43 ± 0.28</td><td> 216.404</td><td> 0.000<sup>*</sup></td></tr><tr><td>Lipid hydroperoxide (nmoL/mL)</td><td>3.63 ± 0.19</td><td>3.10 ± 0.23</td><td>2.44 ± .21</td><td> 240.034</td><td> 0.000<sup>*</sup></td></tr><tr><td>Catalase (kU/L)</td><td>31.53 ± 8.41</td><td>36.12 ± 8.21</td><td>42.25 ± 7.59</td><td> 13.314</td><td> 0.000<sup>*</sup></td></tr><tr><td>Superoxide dismutase (SOD) (U/mL)</td><td>67.25 ± 6.43</td><td>74.76 ± 5.64</td><td>80.83 ± 4.89</td><td> 42.864</td><td> 0.000<sup>*</sup></td></tr><tr><td>Glutathione-S-transferase (GST) (U/mL)</td><td>28.41 ± 4.02</td><td>31.61 ± 3.75</td><td>32.88 ± 3.42</td><td> 11.350</td><td> 0.000<sup>*</sup></td></tr><tr><td>Glutathione (GSH) (nmoL/mL)</td><td>279.3 ± 23.26</td><td>316.76 ± 16.68 </td><td>356.57 ± 11.71</td><td> 140.565</td><td> 0.000<sup>*</sup></td></tr><tr><td>Vitamin C (mg/dL)</td><td>0.76 ± 0.07</td><td>0.85 ± .06</td><td>0.98 ± .05</td><td> 114.403</td><td> 0.000<sup>*</sup></td></tr><tr><td>Cholesterol (mg/dL)</td><td>167.22 ± 10.33</td><td>155.28 ± 7.45</td><td>140.72 ± 14.90</td><td> 41.244</td><td> 0.000<sup>*</sup></td></tr><tr><td>Triglyceride (TG) (mg/dL)</td><td>172.10 ± 14.44</td><td>166.50 ± 13.25</td><td>161.34 ± 11.68</td><td> 5.011</td><td> 0.000<sup>*</sup></td></tr><tr><td>High density lipoprotein (HDL) (mg/dL)</td><td>42.21 ± 5.17</td><td>43.16 ± 5.15</td><td>44.69 ± 4.79</td><td> 1.853</td><td> 0.163</td></tr></table> |
4057d0bc9dfdcf7fadca38707752a8b528181ca456839bc99cec0980cb8bcb57.png | complex | <table><tr><td rowspan="2">Weight management services and products</td><td colspan="3">Perceived availability of services and products (‘Are the following services or products available at the community pharmacy that you go to?’)</td><td colspan="3">Utilization of services and products obtained (‘Have you ever used the following services or bought the following products at the community pharmacy that you go to?’)</td></tr><tr><td>Yes <i>n</i> (%)</td><td>No <i>n</i> (%)</td><td>Not sure <i>n</i> (%)</td><td>Yes <i>n</i> (%)</td><td>No <i>n</i> (%)</td><td>Not sure <i>n</i> (%)</td></tr><tr><td colspan="7"><i>Pharmacy services</i></td></tr><tr><td> Measurement of weight</td><td>409 (56.0)</td><td>276 (37.8)</td><td>45 (6.2)</td><td>234 (32.1)</td><td>396 (54.2)</td><td>100 (13.7)</td></tr><tr><td> Measurement of height</td><td>367 (50.3)</td><td>313 (42.9)</td><td>50 (6.8)</td><td>194 (26.6)</td><td>453 (62.1)</td><td>81 (11.1)</td></tr><tr><td> Calculation of body mass index</td><td>337 (46.2)</td><td>337 (46.2)</td><td>56 (7.7)</td><td>157 (21.5)</td><td>494 (67.7)</td><td>79 (10.8)</td></tr><tr><td> Measurement of waist/hip circumference</td><td>261 (35.8)</td><td>401 (54.9)</td><td>68 (9.3)</td><td>118 (16.2)</td><td>560 (76.7)</td><td>52 (7.1)</td></tr><tr><td> Measurement of body fat percentage</td><td>250 (34.2)</td><td>395 (54.1)</td><td>83 (11.4)</td><td>89 (12.2)</td><td>586 (80.3)</td><td>55 (7.5)</td></tr><tr><td> Measurement of blood pressure</td><td>591 (81.0)</td><td>127 (17.4)</td><td>12 (1.6)</td><td>260 (35.6)</td><td>306 (41.9)</td><td>164 (22.5)</td></tr><tr><td> Measurement of blood glucose</td><td>581 (79.6)</td><td>133 (18.2)</td><td>16 (2.2)</td><td>234 (32.1)</td><td>338 (46.3)</td><td>158 (21.6)</td></tr><tr><td> Measurement of blood cholesterol</td><td>532 (72.9)</td><td>166 (22.7)</td><td>32 (4.4)</td><td>194 (26.6)</td><td>394 (54.0)</td><td>141 (19.3)</td></tr><tr><td> Advice on physical activity to achieve weight loss</td><td>353 (48.4)</td><td>312 (42.7)</td><td>64 (8.8)</td><td>211 (28.9)</td><td>402 (55.1)</td><td>117 (16.0)</td></tr><tr><td> Advice on healthy eating to achieve weight loss</td><td>337 (46.2)</td><td>324 (44.4)</td><td>68 (9.3)</td><td>206 (28.2)</td><td>429 (58.8)</td><td>95 (13.0)</td></tr><tr><td> Referral to doctors and/or dieticians for weight loss</td><td>189 (25.9)</td><td>439 (60.1)</td><td>102 (14.0)</td><td>43 (5.9)</td><td>645 (88.4)</td><td>42 (5.8)</td></tr><tr><td> Referral to slimming centers for weight loss</td><td>141 (19.3)</td><td>477 (65.3)</td><td>109 (14.9)</td><td>35 (4.8)</td><td>653 (89.5)</td><td>41 (5.6)</td></tr><tr><td> Referral to other programs</td><td>25 (3.4)</td><td>479 (65.6)</td><td>85 (11.6)</td><td>9 (1.2)</td><td>505 (69.2)</td><td>99 (13.6)</td></tr><tr><td colspan="7"><i>Weight management products and resources</i></td></tr><tr><td> Supplements (e.g. powdered drinks, herbal products and other non-drug products)</td><td>553 (75.8)</td><td>151 (20.7)</td><td>26 (3.6)</td><td>181 (24.8)</td><td>385 (52.7)</td><td>164 (22.5)</td></tr><tr><td> Creams</td><td>323 (44.2)</td><td>270 (37.0)</td><td>137 (18.8)</td><td>55 (7.5)</td><td>648 (88.8)</td><td>27 (3.7)</td></tr><tr><td> Oral medications</td><td>388 (53.2)</td><td>238 (32.6)</td><td>104 (14.2)</td><td>76 (10.4)</td><td>553 (75.8)</td><td>100 (13.7)</td></tr><tr><td> Information materials (e.g. brochures, leaflets, popular diet books and video CDs)</td><td>283 (38.8)</td><td>308 (42.2)</td><td>139 (19.0)</td><td>80 (11.0)</td><td>589 (80.7)</td><td>61 (8.4)</td></tr></table> |
24307814c79600ceb6d8e05be20cbfb17d0903aa70388be2b75f0c15be249bf4.png | simple | <table><tr><td>Therapeutictarget</td><td>Treatment</td><td>Route ofadministration</td><td>Result</td></tr><tr><td>Indeterminate</td><td>Hypothermia</td><td>IV</td><td>−</td></tr><tr><td></td><td>Hypothermia</td><td>Peritoneal</td><td>−</td></tr><tr><td>MMTP</td><td>Delcasetrib</td><td>IV before reperfusion</td><td>−</td></tr><tr><td></td><td>TR040303</td><td>IV before reperfusion</td><td>−</td></tr><tr><td></td><td>Bendavia</td><td>IV before reperfusion</td><td>−</td></tr><tr><td></td><td>Ciclosporin A</td><td>IV before reperfusion</td><td>+ −</td></tr><tr><td>Nitric oxidesignaling</td><td>Nitrite sodium</td><td>IV</td><td>−</td></tr><tr><td></td><td>Nitrite sodium</td><td>Intracoronary</td><td>−</td></tr><tr><td></td><td>Nitric oxide</td><td>Inhaled</td><td>−</td></tr><tr><td>Pro-survivalkinase</td><td>Copertide</td><td>IV</td><td>+</td></tr><tr><td></td><td>Exenatide</td><td>IV</td><td>+</td></tr><tr><td>Indeterminate</td><td>Metoprolol</td><td>IV</td><td>+</td></tr><tr><td>Indeterminate</td><td>Post-conditioning</td><td>IC balloon inflations</td><td>+ + − −</td></tr><tr><td>Indeterminate</td><td>RIC</td><td>Limb ischemia</td><td>+ + + ++ + + − </td></tr></table> |
698a7c79c97d0f49fc1d424f0a9d52c6cf3f5a323787c21956278f29c49ca048.png | complex | <table><tr><td></td><td></td><td></td><td colspan="2">95% CI</td></tr><tr><td>Variable</td><td>Coefficient (SE)</td><td>Wald</td><td>Lower</td><td>Upper</td></tr><tr><td colspan="5">Low and medium treatments</td></tr><tr><td> Castle</td><td>4.536 (1.844)</td><td>6.11*</td><td>1.39</td><td>15.03</td></tr><tr><td> Nine Mile</td><td>12.936 (1.694)</td><td>18.27***</td><td>4.06</td><td>16.50</td></tr><tr><td> Length (spline 1.9 df)</td><td></td><td>1.57a</td><td></td><td></td></tr><tr><td colspan="5">High treatment</td></tr><tr><td> Castle</td><td>3.525 (1.618)</td><td>6.83**</td><td>1.38</td><td>9.03</td></tr><tr><td> Nine Mile</td><td>9.679 (1.655)</td><td>20.36***</td><td>3.60</td><td>26.05</td></tr><tr><td> Length (spline 2.24 df)</td><td></td><td>19.38***</td><td></td><td></td></tr></table> |
8d192f8c442f810638b95bd8eb33aacfeb15a46c59af7ebaba92319367c0e025.png | simple | <table><tr><td>DFTD</td><td>CTVT</td></tr><tr><td>∼ 16 years old</td><td>∼ 10 000 years old</td></tr><tr><td>Passed by biting</td><td>Passed during coitus</td></tr><tr><td>Close to 100% mortality</td><td>Not fatal (Progression, Stationary and Regression phases)</td></tr><tr><td>No significant infiltration of lymphocytes</td><td>Significant infiltration of lymphocytes during regression</td></tr><tr><td>Schwann cell origin</td><td>Haematopoietic origin (perhaps a macrophage cell)</td></tr><tr><td>MHC class I and class II negative</td><td>MHC class I and class II negative during progression</td></tr><tr><td>Epigenetic regulation of MHC genes</td><td>Epigenetic regulation of MHC genes</td></tr><tr><td>Sensitive to interferon-<i>γ</i></td><td>Sensitive to interferon-<i>γ</i></td></tr><tr><td>Unknown role of immunosuppressive cytokines</td><td>Cytokine regulation of immune response by transforming growth factor-<i>β</i> and interleukin-6</td></tr><tr><td>Low genetic diversity of host</td><td>Host is outbred</td></tr></table> |
f0be4999ef49663ff4e7d2628051a6de774687a1c26c2054247bf5464e381af6.png | simple | <table><tr><td>Cytokine</td><td>Luminex</td><td>Affymetrix</td></tr><tr><td>IL-1α</td><td>2.1</td><td>5.4</td></tr><tr><td>IL-1β</td><td>5.4</td><td>2.6</td></tr><tr><td>IL-2</td><td>Spore only, low expressed</td><td>Spore only, low expressed</td></tr><tr><td>IL-3</td><td>Spore only, low expressed</td><td>Not expressed</td></tr><tr><td>IL-4</td><td>Spore only, low expressed</td><td>Not expressed</td></tr><tr><td>IL-5</td><td>Not expressed</td><td>Mock only, low expressed</td></tr><tr><td>IL-6</td><td>23.7</td><td>27.2</td></tr><tr><td>IL-7</td><td>1.4</td><td>0.7</td></tr><tr><td>IL-8</td><td>0.9</td><td>1.5</td></tr><tr><td>IL-10</td><td>4.6</td><td>2.5</td></tr><tr><td>IL-12p40</td><td>1.4</td><td>3.1</td></tr><tr><td>IL-12p70</td><td>2.0</td><td>Not available</td></tr><tr><td>IL-13</td><td>Spore only, low expressed</td><td>1.4</td></tr><tr><td>IL-15</td><td>Not expressed</td><td>1.5</td></tr><tr><td>GM-CSF</td><td>3.6</td><td>1.6</td></tr><tr><td>IFN-γ</td><td>5.8</td><td>3.8</td></tr><tr><td>TNF-α</td><td>51.6</td><td>10.6</td></tr><tr><td>Eotaxin</td><td>Spore only, low expressed</td><td>1.1</td></tr><tr><td>MCP-1</td><td>2.0</td><td>1.7</td></tr><tr><td>RANTES</td><td>4.7</td><td>3.3</td></tr><tr><td>MIP-1α</td><td>1.7</td><td>3.0</td></tr><tr><td>IP-10</td><td>1.7</td><td>Not available</td></tr><tr><td>IFN-α</td><td>0.8</td><td>2.0</td></tr></table> |
63dd9bca253ecfa38ed7184de3117d1f04016fb598c765d5225b55ad4cb956f4.png | complex | <table><tr><td colspan="2">Interventions</td><td>Mean difference</td><td>Standard error</td><td>p-value</td><td>95% confidence interval</td></tr><tr><td>FISA&DM</td><td>FIS</td><td>−6.80</td><td>3.60</td><td>0.59</td><td>−16.93 to 3.34</td></tr><tr><td> </td><td>Promotion of the survey</td><td>−11.11*</td><td>3.57</td><td>0.02</td><td>−21.21 to −1.01</td></tr><tr><td> </td><td>Multiple letters</td><td>−16.65*</td><td>3.63</td><td><0.001</td><td>−26.89 to −6.40</td></tr><tr><td> </td><td>Control</td><td>−10.02</td><td>3.60</td><td>0.06</td><td>−20.19 to 0.15</td></tr><tr><td>FIS</td><td>Promotion of the survey</td><td>−4.32</td><td>3.47</td><td>1.00</td><td>−14.13 to 5.50</td></tr><tr><td> </td><td>Multiple letters</td><td>−9.65</td><td>3.53</td><td>0.06</td><td>−19.82 to 0.12</td></tr><tr><td> </td><td>Control</td><td>−3.22</td><td>3.50</td><td>1.00</td><td>−13.11 to 6.67</td></tr><tr><td>Promotion of the survey</td><td>Multiple letters</td><td>−5.53</td><td>3.51</td><td>1.00</td><td>−15.46 to 4.40</td></tr><tr><td> </td><td>Control</td><td>1.10</td><td>3.50</td><td>1.00</td><td>−8.76 to 10.95</td></tr><tr><td>Multiple letters</td><td>Control</td><td>6.63</td><td>3.54</td><td>0.62</td><td>−3.38 to 16.63</td></tr></table> |
4b5376f147732ce752c879e86fb86d20e8fb3c2b7b19d2feaa7754f4989ef2f0.png | complex | <table><tr><td>Baseline<i>Usual Activities</i></td><td colspan="3">Specific "usually enjoyed activity" identified</td><td></td></tr><tr><td></td><td>No</td><td colspan="2">Yes</td><td></td></tr><tr><td></td><td>n (%)</td><td>n (%)</td><td>Importance(IQR)</td><td>Total</td></tr><tr><td>No problems</td><td>46 (48.9)</td><td>142 (45.7)</td><td>76 (30)</td><td>188</td></tr><tr><td>Some problems</td><td>45 (47.9)</td><td>142 (45.7)</td><td>88 (30)</td><td>187</td></tr><tr><td>Unable</td><td>3 (3.2)</td><td>27 (8.7)</td><td>93 (21)</td><td>30</td></tr><tr><td>Total</td><td>94</td><td>311</td><td></td><td>405</td></tr><tr><td>12 months<i>Usual Activities</i></td><td colspan="3">12 months "able to take part in usually enjoyed activity"</td><td></td></tr><tr><td></td><td>no</td><td colspan="2">yes</td><td>Total</td></tr><tr><td>No problems</td><td>21 (42.0)</td><td colspan="2">120 (63.5)</td><td>141</td></tr><tr><td>Some problems</td><td>24 (48.0)</td><td colspan="2">66 (34.9)</td><td>90</td></tr><tr><td>Unable</td><td>5 (10.0)</td><td colspan="2">3 (1.6)</td><td>8</td></tr><tr><td>Total</td><td>50</td><td colspan="2">189</td><td>239</td></tr></table> |
b40c836cf5263e6d361c8bf7c21cac76802f320f32aafe9559155fd8c39512e9.png | simple | <table><tr><td></td><td>Cohort <i>N</i> = 151</td></tr><tr><td>Age (mean years ± SD)</td><td>30 ± 11</td></tr><tr><td><18 years of age</td><td>43 (28)</td></tr><tr><td>Range (years)</td><td>13–61</td></tr><tr><td>Race</td><td></td></tr><tr><td>African-American</td><td>57 (38)</td></tr><tr><td>Caucasian</td><td>57 (38)</td></tr><tr><td>Hispanic</td><td>37 (24)</td></tr><tr><td>County of residence</td><td></td></tr><tr><td>Dallas</td><td>130 (86)</td></tr><tr><td>Out of county (TX)</td><td>18 (12)</td></tr><tr><td>Out of state</td><td>3 (2)</td></tr><tr><td>Mode of transport to the hospital</td><td></td></tr><tr><td>Emergency medical services</td><td>16 (11)</td></tr><tr><td>Police</td><td>69 (46)</td></tr><tr><td>Self</td><td>64 (42)</td></tr><tr><td>Unknown</td><td>2 (1)</td></tr><tr><td>Trauma service evaluation</td><td>15 (10)</td></tr></table> |
b61aa5518933ebcc9a2c7985f73eb82ebdfe6e7ea4cb5ede1be802213dae6319.png | simple | <table><tr><td></td><td>Estimate</td><td>Standard Error</td><td>Z Value</td><td>P(>|Z|)</td></tr><tr><td>Clean and Income</td><td>−0.00</td><td>0.00</td><td>− 0.75</td><td>0.45</td></tr><tr><td>Clean and White</td><td>−0.95</td><td>1.52</td><td>−0.63</td><td>0.53</td></tr><tr><td>Clogged and Income</td><td>0.00</td><td>0.00</td><td>0.85</td><td>0.40</td></tr><tr><td>Clogged and White</td><td>0.64</td><td>1.70</td><td>0.38</td><td>0.70</td></tr><tr><td>Bottle and Income</td><td>−0.00</td><td>0.00</td><td>−0.89</td><td>0.37</td></tr><tr><td>Bottle and White</td><td>−0.31</td><td>1.47</td><td>−0.21</td><td>0.83</td></tr><tr><td>Handicap and Income</td><td>−0.00</td><td>0.00</td><td>−2.09</td><td>0.04</td></tr><tr><td>Handicap and White</td><td>1.42</td><td>1.65</td><td>0.86</td><td>0.39</td></tr></table> |
8dcce189e8cc36369d1651484614d6214e16277b8a130884c38fb617021f12bd.png | simple | <table><tr><td>Factors</td><td>Reactivation<i>N</i> = 97</td><td>No Reactivation<i>N</i> = 189</td><td>Univariate<i>P</i> value</td><td>Multivariate<i>P</i> Value</td><td>Odds ratio(95% CI)</td></tr><tr><td>Hematological malignancy</td><td></td><td></td><td>0.332</td><td>NA</td><td></td></tr><tr><td> AML</td><td>29</td><td>46</td><td></td><td></td><td></td></tr><tr><td>ALL</td><td>3</td><td>10</td><td></td><td></td><td></td></tr><tr><td>Lymphoma</td><td>46</td><td>96</td><td></td><td></td><td></td></tr><tr><td>CML/MPN</td><td>1</td><td>5</td><td></td><td></td><td></td></tr><tr><td>CLL</td><td>2</td><td>3</td><td></td><td></td><td></td></tr><tr><td>Myeloma</td><td>10</td><td>21</td><td></td><td></td><td></td></tr><tr><td>MDS/AA</td><td>6</td><td>8</td><td></td><td></td><td></td></tr><tr><td>Age > 65 year</td><td></td><td></td><td>0.052</td><td>0.198</td><td></td></tr><tr><td> Yes</td><td>11</td><td>57</td><td></td><td></td><td></td></tr><tr><td> No</td><td>86</td><td>132</td><td></td><td></td><td></td></tr><tr><td>Gender</td><td></td><td></td><td>0.781</td><td>NA</td><td></td></tr><tr><td> Man</td><td>55</td><td>106</td><td></td><td></td><td></td></tr><tr><td> Woman</td><td>42</td><td>83</td><td></td><td></td><td></td></tr><tr><td>Hepatitis C</td><td></td><td></td><td>0.180</td><td>0.453</td><td></td></tr><tr><td> Yes</td><td>4</td><td>4</td><td></td><td></td><td></td></tr><tr><td> No</td><td>93</td><td>185</td><td></td><td></td><td></td></tr><tr><td>Liver cirrhosis</td><td></td><td></td><td>0.906</td><td>NA</td><td></td></tr><tr><td> Yes</td><td>4</td><td>7</td><td></td><td></td><td></td></tr><tr><td> No</td><td>93</td><td>182</td><td></td><td></td><td></td></tr><tr><td>Hepatocellular carcinoma</td><td></td><td></td><td>0.032</td><td><0.001</td><td>0.101(0.029–0.355)</td></tr><tr><td> Yes</td><td>3</td><td>1</td><td></td><td></td><td></td></tr><tr><td> No</td><td>94</td><td>188</td><td></td><td></td><td></td></tr><tr><td>Diabetes mellitus</td><td></td><td></td><td>0.388</td><td>NA</td><td></td></tr><tr><td> Yes</td><td>10</td><td>20</td><td></td><td></td><td></td></tr><tr><td> No</td><td>87</td><td>169</td><td></td><td></td><td></td></tr><tr><td>Allogeneic transplantation</td><td></td><td></td><td>0.113</td><td>0.269</td><td></td></tr><tr><td> Yes</td><td>28</td><td>31</td><td></td><td></td><td></td></tr><tr><td> No</td><td>69</td><td>158</td><td></td><td></td><td></td></tr><tr><td>Antiviral prophylaxis</td><td></td><td></td><td><0.001</td><td><0.001</td><td>4.631(2.902–7.390)</td></tr><tr><td> Yes</td><td>26</td><td>145</td><td></td><td></td><td></td></tr><tr><td> No</td><td>71</td><td>44</td><td></td><td></td><td></td></tr></table> |
0c8c2fc75d1fb05b28f2cba9d61ccaeee3d982726ace846534367473446c6544.png | complex | <table><tr><td></td><td>D-dimer</td><td>Plasminogen</td><td>PAI-1</td></tr><tr><td></td><td>(ng/mL)</td><td>(%)</td><td>(ng/mL)</td></tr><tr><td colspan="4">Idiopathic ON</td></tr><tr><td> mean (SD)</td><td>241 (132)</td><td>115 (18) <sup>b</sup></td><td>4.6 (2.6)</td></tr><tr><td> median</td><td>173</td><td>118</td><td>4.7</td></tr><tr><td> range</td><td>86–553</td><td>72–149</td><td>1.2–10.5</td></tr><tr><td colspan="4">Corticosteroid-associated ON</td></tr><tr><td> mean (SD)</td><td>384 (274) <sup>a</sup></td><td>104 (15)</td><td>3.6 (1.9)</td></tr><tr><td> median</td><td>333</td><td>101</td><td>2.9</td></tr><tr><td> range</td><td>85–1000</td><td>84–129</td><td>1.5–7.1</td></tr><tr><td colspan="4">Healthy controls</td></tr><tr><td> mean (SD)</td><td>173 (72)</td><td>104 (16)</td><td>3.4 (1.8)</td></tr><tr><td> median</td><td>164</td><td>101</td><td>3.2</td></tr><tr><td> range</td><td>65–338</td><td>65–129</td><td>0.6–8</td></tr></table> |
ad2e8de7c632ed39f484ac6394fe7bad96351918dc9a86a10a03a814084e96b8.png | complex | <table><tr><td> </td><td colspan="3">Pooled raw data</td><td colspan="3">Means per dog (n > 5)</td></tr><tr><td>Declination rate</td><td>0%</td><td>0.1-2%</td><td>>2%</td><td>0%</td><td>0.1-2%</td><td>>2%</td></tr><tr><td>Number of observations</td><td>607</td><td>542</td><td>744</td><td>43</td><td>36</td><td>39</td></tr><tr><td>Mean vector (μ)</td><td>176°/356°</td><td>111°/291°</td><td>109°/289°</td><td>173°/353°</td><td>104°/184°</td><td>96°/276°</td></tr><tr><td>Length of mean vector (r)</td><td>0.216</td><td>0.106</td><td>0.03</td><td>0.598</td><td>0.283</td><td>0.194</td></tr><tr><td>Circular standard deviation</td><td>50°</td><td>61°</td><td>76°</td><td>29°</td><td>45°</td><td>52°</td></tr><tr><td>95% Confidence interval (-/+) for μ</td><td>168°-183°</td><td>-</td><td>-</td><td>164°-182°</td><td>81°-127°</td><td>-</td></tr><tr><td>99% Confidence interval (-/+) for μ</td><td>166°-185°</td><td>-</td><td>-</td><td>161°-185°</td><td>74°-134°</td><td>-</td></tr><tr><td>Rayleigh test (Z)</td><td>28.248</td><td>6.133</td><td>0.672</td><td>15.353</td><td>2.891</td><td>1.464</td></tr><tr><td>Rayleigh test (p)</td><td><10<sup>-12</sup></td><td>0.002</td><td>0.511</td><td>6.20⋅10<sup>-8</sup></td><td>0.055</td><td>0.233</td></tr></table> |
b6c42ae4b2df1392998c79e95a86cbfc34f3c5f7ae2199a555d82030fd7ee2b3.png | simple | <table><tr><td>Author</td><td> Design</td><td>Subjects</td><td>Most common sport</td><td>Cardiovascular disease found</td></tr><tr><td>Corrado et al. [1]</td><td>Prospective</td><td>23/300 athletes, ages 12–35 </td><td>(1) Soccer(2) Swimming</td><td>(1) CAD<sup>a</sup>(2) ARVC</td></tr><tr><td>de Noronha et al. [6]</td><td>Prospective</td><td>118 cases, mean age 28</td><td>(1) Soccer(2) Running</td><td>(1) Isolated LVH<sup>b</sup>(2) Normal heart(3) ARVC</td></tr><tr><td>Maron et al. [3]</td><td>Retrospective</td><td>60 international athletes (ages 19 ± 3) and 213 US Athletes (ages 14 ± 9 years)</td><td>Soccer</td><td>Commotio Cordis</td></tr><tr><td>Maron et al. [2]</td><td>Retrospective</td><td>1866 athletes (ages 16 ± 4)</td><td>(1) Basketball(2) Football(3) Soccer</td><td>(1) HCM<sup>b</sup> (2) CCA </td></tr><tr><td>Bille et al. [4]</td><td>Retrospective</td><td>388 athletes </td><td>(1) Soccer(2) Running(3) Basketball</td><td>(1) HCM<sup>b</sup> (2) CCA</td></tr><tr><td>Allouche et al. [7]</td><td>Retrospective</td><td>32 athletes</td><td>(1) Running(2) Soccer</td><td>(1) HCM<sup>b</sup> (2) ARVC</td></tr><tr><td>Suárez-Mier and Aguilera [8]</td><td>Retrospective</td><td>61 athletes, mean ages 31.9 ± 14</td><td>(1) Cycling(2) Soccer</td><td>(1) ARVC<sup>c</sup> (2) Isolated LVH</td></tr><tr><td>McConnell and Collins [9]</td><td>Case study</td><td>24 y.o. female</td><td>Soccer</td><td>Hypoplastic left coronary artery</td></tr><tr><td>Chen and Sheppard [10]</td><td>Case study</td><td>22 y.o. male</td><td>Soccer</td><td>Ebstein anomaly due to hemangioma</td></tr><tr><td>Zeller et al. [11]</td><td>Case study</td><td>26 y.o. male</td><td>Soccer</td><td>Marked early repolarization on ECG two weeks prior to SCD; autopsy was normal</td></tr><tr><td>Pellissier et al. [12]</td><td>Case study</td><td>15 y.o. male</td><td>Soccer</td><td>Left coronary artery arising from the right anterior sinus with an oblique course between the aorta and the pulmonary artery trunk</td></tr><tr><td>Pacchioni et al. [13]</td><td>Case study</td><td>18 y.o. male</td><td>Soccer</td><td>ARVC</td></tr><tr><td>Ronneberger et al. [14]</td><td>Case study</td><td>8 y.o. male</td><td>Soccer</td><td>Myxomatous mitral valve with lacerations of the posterior cusp and the left vestibular endocardium and left ventricular hypertrophy</td></tr><tr><td>Ottaviani et al. [15]</td><td>Case study</td><td>13 y.o. male</td><td>Soccer</td><td>Abnormal origin of left coronary artery from the right aortic sinus of Valsalva</td></tr><tr><td>Iskandar and Thompson [16]</td><td>Case study</td><td>14 y.o male </td><td>Soccer</td><td>Acute angle takeoff of the left main coronary artery and a transverse slit-like opening with a fibrous cushion, which created a kink near its origin</td></tr><tr><td>Meel [17]</td><td>Case study</td><td>22 y.o. male</td><td>Soccer</td><td>Abnormal origin of the left coronary artery from the right sinus of Valsalva</td></tr></table> |
89fae807f9d838a86a608962cd426417a50610d5fbf8d761c3e8c547171f094b.png | complex | <table><tr><td rowspan="2">Participant<sup>a</sup></td><td colspan="4">Classifications for sensory profile quadrants<sup>b</sup></td><td rowspan="2">Number of quadrants affected</td></tr><tr><td>Low registration</td><td>Sensation seeking</td><td>Sensory sensitivity</td><td>Sensation avoiding</td></tr><tr><td>1</td><td>More than most</td><td>Less than most</td><td>More than most</td><td>More than most</td><td>4</td></tr><tr><td>2</td><td>More than most</td><td>Similar to most</td><td>More than most</td><td>More than most</td><td>3</td></tr><tr><td>3</td><td>More than most</td><td>Less than most</td><td>Much more than most</td><td>More than most</td><td>4</td></tr><tr><td>4</td><td>More than most</td><td>Similar to most</td><td>More than most</td><td>More than most</td><td>3</td></tr><tr><td>5</td><td>More than most</td><td>Similar to most</td><td>More than most</td><td>More than most</td><td>3</td></tr><tr><td>6</td><td>More than most</td><td>Similar to most</td><td>More than most</td><td>Similar to most</td><td>2</td></tr><tr><td>7</td><td>Similar to most</td><td>Similar to most</td><td>Less than most</td><td>Similar to most</td><td>1</td></tr><tr><td>8</td><td>More than most</td><td>Less than most</td><td>Similar to most</td><td>Similar to most</td><td>2</td></tr><tr><td>9</td><td>Similar to most</td><td>Less than most</td><td>Similar to most</td><td>Similar to most</td><td>1</td></tr><tr><td>10</td><td>Similar to most</td><td>Less than most</td><td>Much more than most</td><td>Similar to most</td><td>2</td></tr><tr><td>11</td><td>More than most</td><td>Less than most</td><td>More than most</td><td>Similar to most</td><td>3</td></tr><tr><td>12</td><td>More than most</td><td>Similar to most</td><td>More than most</td><td>More than most</td><td>3</td></tr><tr><td>13</td><td>Much more most</td><td>Similar to most</td><td>Much more than most</td><td>More than most</td><td>3</td></tr><tr><td>14</td><td>Much more most</td><td>Similar to most</td><td>More than most</td><td>Similar to most</td><td>2</td></tr><tr><td>Percentage of participants scoring outside the normal range</td><td>79</td><td>43</td><td>93</td><td>50</td><td></td></tr><tr><td rowspan="2">Average quadrant scores, ranges and standard deviations</td><td><i>M</i> = 43 (26–57)</td><td><i>M</i> = 44 (35–54)</td><td><i>M</i> = 42 (22–55)</td><td><i>M</i> = 43 (28–55)</td><td></td></tr><tr><td><i>SD</i> = 7.48</td><td><i>SD</i> = 6.22</td><td><i>SD</i> = 8.84</td><td><i>SD</i> = 8.57</td><td></td></tr></table> |
798de59205b03f5ce02bbd25c5881087c024866acbd4128ad5ce260787787430.png | complex | <table><tr><td>Fixed effects</td><td colspan="3">Liking</td><td colspan="3">Representational</td><td colspan="3">Evoked</td></tr><tr><td></td><td>Estimate</td><td><i>SE</i></td><td><i>t</i></td><td>Estimate</td><td><i>SE</i></td><td><i>t</i></td><td>Estimate</td><td><i>SE</i></td><td><i>t</i></td></tr><tr><td>Condition 1 (neutral)</td><td>1.985</td><td>0.108</td><td>18.389<sup>∗∗</sup></td><td>134.830</td><td>6.712</td><td>20.088<sup>∗∗</sup></td><td>194.665</td><td>10.789</td><td>18.042<sup>∗∗</sup></td></tr><tr><td>Condition 2 (crying)</td><td>-1.261</td><td>0.089</td><td>-14.093<sup>∗∗</sup></td><td>-83.055</td><td>6.004</td><td>-13.834<sup>∗∗</sup></td><td>-133.280</td><td>10.002</td><td>-13.325<sup>∗∗</sup></td></tr><tr><td>Condition 3 (laughing)</td><td>-0.433</td><td>0.084</td><td>-5.163<sup>∗∗</sup></td><td>-27.716</td><td>6.799</td><td>-4.076<sup>∗∗</sup></td><td>6.908</td><td>11.505</td><td>0.600</td></tr><tr><td>SAS</td><td>0.042</td><td>0.015</td><td>2.838<sup>∗∗</sup></td><td>3.017</td><td>0.810</td><td>3.723<sup>∗∗</sup></td><td>3.538</td><td>1.357</td><td>2.607<sup>∗∗</sup></td></tr><tr><td>Condition 2 × SAS</td><td>-0.010</td><td>0.013</td><td>-0.796</td><td>-0.735</td><td>0.749</td><td>-0.982</td><td>-0.956</td><td>1.251</td><td>-0.764</td></tr><tr><td>Condition 3 × SAS</td><td>-0.028</td><td>0.010</td><td>-2.761<sup>∗∗</sup></td><td>-2.635</td><td>0.839</td><td>-3.141<sup>∗∗</sup></td><td>0.212</td><td>1.491</td><td>0.142</td></tr></table> |
3c8e372c8f9eecf8096c011755973d0b316ff33ee7e2a86f9de1d936a8e1b90e.png | simple | <table><tr><td></td><td><i>Fieldl</i></td><td><i>Field3</i></td><td><i>Field4</i></td><td><i>Field6</i></td><td><i>Field7</i></td></tr><tr><td>Dose 1<sup>a</sup></td><td>35.4</td><td>35.5</td><td>34.3</td><td>39.5</td><td>36.3</td></tr><tr><td>Dose 2<sup>b</sup></td><td>30.6</td><td>34.1</td><td>35.3</td><td>30.8</td><td>34.3</td></tr><tr><td>Dose 3<sup>c</sup></td><td>30.6</td><td>33.8</td><td>34.3</td><td>30.8</td><td>34.8</td></tr></table> |
0724335769f4055f5bed1c6b58f6374d92808bb32d54843e97ff3a53f3e902a7.png | simple | <table><tr><td>Arthrosis grade on MRI</td><td>Preoperatively</td><td>Postoperatively</td></tr><tr><td>0</td><td>8</td><td>7</td></tr><tr><td>1</td><td>17</td><td>13</td></tr><tr><td>2</td><td>23</td><td>25</td></tr><tr><td>3</td><td>7</td><td>8</td></tr><tr><td>4</td><td>6</td><td>8</td></tr><tr><td><i>P</i> Value</td><td><i>Z</i> = − 0.911</td><td><i>P</i> = 0.36</td></tr></table> |
fc4c334cdcd867bd18bfab9c28d1b6b8ad1e748dc0527faac8baed95e494a516.png | complex | <table><tr><td></td><td></td><td colspan="3">Illumina</td><td colspan="2">qPCR</td></tr><tr><td>Name</td><td>Component, accession</td><td>Log FC</td><td>Log CPM</td><td>FDR</td><td>Log FC</td><td>Range FC</td></tr><tr><td>FABP</td><td>comp254629_c0 ES387222</td><td>−2.24</td><td>8.57</td><td>4.55E-09</td><td>−3.45</td><td>15.6</td></tr><tr><td>ELOV</td><td>comp267151_c1 ES387246</td><td>−4.72</td><td>9.31</td><td>4.36E-16</td><td>−4.74</td><td>30.0</td></tr><tr><td>HR78</td><td>comp265637_c0 KJ026941</td><td>−2.06</td><td>0.79</td><td>1.02E-04</td><td>−1.26</td><td>12.8</td></tr><tr><td>ERR</td><td>comp273411_c0 KJ026943</td><td>−2.17</td><td>4.89</td><td>1.14E-08</td><td>−1.84</td><td>5.3</td></tr><tr><td>HR3</td><td>comp264460_c0 KJ026938</td><td>3.21</td><td>4.48</td><td>2.59E-14</td><td>3.84</td><td>64.2</td></tr><tr><td>HR38a</td><td>comp270260_c0 KJ026939</td><td>2.65</td><td>3.63</td><td>8.58E-12</td><td>2.25</td><td>5.9</td></tr><tr><td>Vtg</td><td>comp274635_c1 KJ026944</td><td>3.20</td><td>8.14</td><td>3.45E-10</td><td>1.15</td><td>597.9</td></tr><tr><td>Torso-like</td><td>comp266966_c0 KJ026945</td><td>9.26</td><td>7.40</td><td>1.19e-84</td><td>8.24</td><td>1024.2</td></tr><tr><td>FTZ-F1</td><td>comp268775_c0 KJ026942</td><td>3.25</td><td>5.97</td><td>3.05E-16</td><td>4.25</td><td>32.0</td></tr><tr><td>HR38b</td><td>comp267178_c0 KJ026940</td><td>2.26</td><td>4.27</td><td>6.58E-10</td><td>1.07</td><td>7.8</td></tr><tr><td>EcR</td><td>comp263662_c0 EF583877</td><td>1.10</td><td>3.13</td><td>0.39</td><td>1.06</td><td>3.4</td></tr><tr><td>Fem1</td><td>comp269877_c0 KJ026947</td><td>4.43</td><td>7.08</td><td>1.67E-17</td><td>1.33</td><td>7.6</td></tr></table> |
749efb7abed3791ccc55ef2bf53f8a387e63581d833473ccc1ba48976e2c3a71.png | complex | <table><tr><td></td><td>True</td><td rowspan="2">Healthy Control</td><td rowspan="2">sALS Patient</td><td rowspan="2">ALS Mutation Carrier</td><td rowspan="2">fALS Patient</td></tr><tr><td>Prediction</td><td></td></tr><tr><td colspan="2">healthy Control</td><td>14(16)</td><td>6(-)</td><td>0(1)</td><td>0(0)</td></tr><tr><td colspan="2">sALS Patient</td><td>3(-)</td><td>8(-)</td><td>2(-)</td><td>0(-)</td></tr><tr><td colspan="2">ALS Mutation Carrier</td><td>0(1)</td><td>2(-)</td><td>8(7)</td><td>1(2)</td></tr><tr><td colspan="2">fALS Patient</td><td>0(0)</td><td>2(-)</td><td>2(4)</td><td>5(4)</td></tr></table> |
d1ef9db27da0456c0e60c652f5cb7695373fc7ee6ec98c04afc2ab8897fcfb18.png | complex | <table><tr><td>Nr.</td><td>Effect</td><td>Effect type</td><td>Estimate</td><td>Std-Error</td><td><i>P</i>-value</td><td>N</td></tr><tr><td rowspan="3">a</td><td>Age class (mother = 0)</td><td>Fixed</td><td>−0.1</td><td>0.25</td><td>0.672</td><td>2</td></tr><tr><td>Site (Tuanan = 0)</td><td>Fixed</td><td>−0.52</td><td>0.25</td><td>0.035</td><td>2</td></tr><tr><td>Individual</td><td>Random</td><td>-</td><td>-</td><td>-</td><td>15 (32)</td></tr><tr><td rowspan="3">b</td><td>Age</td><td>Fixed</td><td>0.02</td><td>0.1</td><td>0.863</td><td>cont.</td></tr><tr><td>Site (Tuanan = 0)</td><td>Fixed</td><td>−0.69</td><td>0.3</td><td>0.021</td><td>2</td></tr><tr><td>Individual</td><td>Random</td><td>-</td><td>-</td><td>-</td><td>8 (17)</td></tr></table> |
882112dd3ee2a0ca5242ec5ff6aa11fadae2f947e3f369973fe35e2516674dc3.png | complex | <table><tr><td></td><td>Total number of participating residents (% of total)</td><td>Number of residents with burnout (% of total)</td><td><i>p</i>-value of difference in burnout rate per characteristic</td></tr><tr><td colspan="4">Gender</td></tr><tr><td> Male</td><td>96 (40.7)</td><td>45 (46.9)</td><td></td></tr><tr><td> Female</td><td>140 (59,3)</td><td>53 (37.9)</td><td></td></tr><tr><td></td><td></td><td></td><td>0.17</td></tr><tr><td colspan="4">Years in training</td></tr><tr><td> 1</td><td>52 (22.2)</td><td>22 (42.3)</td><td></td></tr><tr><td> 2</td><td>23 (9.7)</td><td>11 (47.8)</td><td></td></tr><tr><td> 3</td><td>31 (13.1)</td><td>8 (25.8)</td><td></td></tr><tr><td> 4</td><td>50 (21.2)</td><td>24 (48.0)</td><td></td></tr><tr><td> 5</td><td>45 (19.1)</td><td>18 (40.0)</td><td></td></tr><tr><td> 6</td><td>25 (10.6)</td><td>11 (44.0)</td><td></td></tr><tr><td> 7</td><td>8 (3.4)</td><td>2 (25.0)</td><td></td></tr><tr><td></td><td></td><td></td><td>0.49</td></tr><tr><td colspan="4">Type of specialty</td></tr><tr><td> Surgical</td><td>57 (24.2)</td><td>26 (45.6)</td><td></td></tr><tr><td> Medical</td><td>144 (61.0)</td><td>59 (41.0)</td><td></td></tr><tr><td> Supportive</td><td>34 (14.4)</td><td>12 (35.3)</td><td></td></tr><tr><td> missing</td><td>1 (0.4)</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>0.62</td></tr><tr><td colspan="4">Satisfaction with work/life balance</td></tr><tr><td> Very dissatisfied</td><td>31 (13.1)</td><td>21 (67.7)</td><td></td></tr><tr><td> Dissatisfied</td><td>4 (1.7)</td><td>2 (50.0)</td><td></td></tr><tr><td> Neutral</td><td>69 (29.2)</td><td>14 (20.3)</td><td></td></tr><tr><td> Satisfied</td><td>130 (55.1)</td><td>61 (46.9)</td><td></td></tr><tr><td> Very satisfied</td><td>2 (0.8)</td><td>0 (0.0)</td><td></td></tr><tr><td></td><td></td><td></td><td>< 0.001</td></tr><tr><td colspan="4">Quality of life</td></tr><tr><td> As bad as it can be</td><td>12 (5.1)</td><td>10 (83.3)</td><td></td></tr><tr><td> Bad</td><td>59 (25.0)</td><td>37 (62.7)</td><td></td></tr><tr><td> Neutral</td><td>79 (33.5)</td><td>37 (46.8)</td><td></td></tr><tr><td> Good</td><td>77 (32.6)</td><td>14 (18.2)</td><td></td></tr><tr><td> As good as it can be</td><td>9 (3.8)</td><td>0 (0.0)</td><td></td></tr><tr><td></td><td></td><td></td><td>< 0.001</td></tr><tr><td>Burned out<sup>a</sup></td><td>98 (41.5)</td><td></td><td></td></tr><tr><td> Emotionally exhausted<sup>b</sup></td><td>125 (53.0)</td><td></td><td></td></tr><tr><td> Depersonalized<sup>b</sup></td><td>125 (53.0)</td><td></td><td></td></tr><tr><td> Reduced personal accomplishment<sup>b</sup></td><td>60 (23.4)</td><td></td><td></td></tr></table> |
36e4366697b964fc863e53af7f3b2d526b92a5756a020c1082c7d4f25bbb2403.png | simple | <table><tr><td>Prevention level</td><td>Goal</td><td>Child-protective examples</td></tr><tr><td>Zero-order</td><td>Prevent the development of a hazard</td><td>Urban planning to reduce GHGs from vehicular traffic and increase pedestrian access, resulting in improved air quality and increased physical activity (Sheffield and Galvez 2009)</td></tr><tr><td>Primary</td><td>Block interaction between hazard and human</td><td>Relocation of low-lying island populations facing increased risk of flooding, or distribution of mosquito nets</td></tr><tr><td>Secondary</td><td>Prevent effects after exposure to the hazard</td><td>Activation of early warning systems before heat waves</td></tr><tr><td>Tertiary</td><td>Reduce morbidity and mortality, avoid complications, and restore function</td><td>Postdisaster restoration of chronic care services</td></tr></table> |
e42f8a6e66bdd674b6db828ad0b35c5cca1e69ffe420e74adfbf58e082d9ead7.png | simple | <table><tr><td>Mode</td><td>Controlled/Known Parameters</td><td>Parameters to Estimate</td></tr><tr><td>Calibration</td><td>Main measurement parameters</td><td>System calibration parameters</td></tr><tr><td>Normal estimation</td><td>System calibration parameters</td><td>Main measurement parameters</td></tr></table> |
70c09be97ebb51cec9966bf44337a38a9ac6d659c5e4bfc6569ade770d519e36.png | simple | <table><tr><td> </td><td>Mean (SD)</td><td>95%-CI</td><td>Minimum</td><td>Maximum</td></tr><tr><td>Etanercept (n = 233)</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Outpatient care</td><td>1,113 (998)</td><td>984-1,241</td><td>0</td><td>5,775</td></tr><tr><td>Medications</td><td>17,751 (10,024)</td><td>16,457-19,045</td><td>1,058</td><td>102,156</td></tr><tr><td>Laboratory tests</td><td>585 (531)</td><td>517-654</td><td>0</td><td>4,114</td></tr><tr><td>Outpatient care in hospitals</td><td>453 (1,206)</td><td>297-609</td><td>0</td><td>12,382</td></tr><tr><td>Devices and aids</td><td>60 (220)</td><td>32-89</td><td>0</td><td>1,827</td></tr><tr><td>Other claims</td><td>593 (1,801)</td><td>360-825</td><td>0</td><td>19,749</td></tr><tr><td><i>Total direct cost (etanercept</i>)</td><td>20,555 (10,740)</td><td>19,169-21,942</td><td>1,589</td><td>111,994</td></tr><tr><td>Adalimumab (n = 201)</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Outpatient care</td><td>1,276 (965)</td><td>1,142-1,410</td><td>0</td><td>5,798</td></tr><tr><td>Medications</td><td>21,315 (9,008)</td><td>20,062-22,568</td><td>1,169</td><td>58,129</td></tr><tr><td>Laboratory tests</td><td>634 (521)</td><td>561-706</td><td>0</td><td>4,840</td></tr><tr><td>Outpatient care in hospitals</td><td>418 (891)</td><td>294-542</td><td>0</td><td>5,913</td></tr><tr><td>Devices and aids</td><td>90 (358)</td><td>40-140</td><td>0</td><td>4,004</td></tr><tr><td>Other claims</td><td>419 (810)</td><td>306-531</td><td>0</td><td>7,241</td></tr><tr><td><i>Total direct cost (adalimumab)</i></td><td>24,152 (9,403)</td><td>22,844-25,460</td><td>1,994</td><td>61,613</td></tr><tr><td>Infliximab (n = 121)</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Outpatient care</td><td>1,087 (1,243)</td><td>863-1,310</td><td>0</td><td>6,358</td></tr><tr><td>Medications</td><td>22,666 (10,625)</td><td>20,754-24,579</td><td>4,247</td><td>68,590</td></tr><tr><td>Laboratory tests</td><td>1,024 (751)</td><td>889-1,159</td><td>0</td><td>4,176</td></tr><tr><td>Outpatient care in hospitals</td><td>2,363 (2,817)</td><td>1,856-2,871</td><td>0</td><td>23,271</td></tr><tr><td>Devices and aids</td><td>151 (258)</td><td>104-197</td><td>0</td><td>1,722</td></tr><tr><td>Other claims</td><td>323 (703)</td><td>196-449</td><td>0</td><td>4,304</td></tr><tr><td><i>Total direct cost (infliximab)</i></td><td>27,614 (11,860)</td><td>25,479-29,748</td><td>5,733</td><td>72,233</td></tr></table> |
32e2431b0c1f3b955f1aadb1be79fd74a24702ec171d232f059ad345c0e94495.png | simple | <table><tr><td>Abbreviation</td><td>Description, Definition</td></tr><tr><td> </td><td>Tissue mapping in specific compartments</td></tr><tr><td>ABM</td><td>Adipose bone marrow</td></tr><tr><td>TV</td><td>Total volume of the body (from ankle to wrist), without INF</td></tr><tr><td>TVV</td><td>Total visceral volume: includes intrathoracic and intraabdominal volume.</td></tr><tr><td>TSV</td><td>Total somatic volume (TV without TVV).</td></tr><tr><td>TLT</td><td>Total lean tissue</td></tr><tr><td>VLT</td><td>Visceral lean tissue: includes lean tissue of intrathoracic and intraabdominal organs.</td></tr><tr><td>SLT</td><td>Somatic lean tissue: mostly muscles</td></tr><tr><td>TAT</td><td>Total adipose tissue (without INF)</td></tr><tr><td>SAT</td><td>Somatic adipose tissue (TAT without VAT)</td></tr><tr><td>TAST</td><td>Total adipose soft tissue (TAT without ABM)</td></tr><tr><td>SAST</td><td>Somatic adipose soft tissue (TAT without ABM and VAT)</td></tr><tr><td>SCAT</td><td>Subcutaneous adipose tissue (SAST without IMAT)</td></tr><tr><td>IMAT</td><td>Intermuscular adipose tissue (SAST without SCAT)</td></tr><tr><td>VAT</td><td>Visceral adipose tissue (IAAT + MAT without INF)</td></tr><tr><td>IAAT</td><td>Intraabdominal adipose tissue: retroperitoneal and intraperitoneal (mesenteric, omental) fat depots (without INF)</td></tr><tr><td>MAT</td><td>Intrathoracic, mainly mediastinal adipose tissue</td></tr><tr><td>INF</td><td>(Undigested) intraluminal nutrition fat in the gastrointestinal tract</td></tr><tr><td> </td><td>Tissue mapping of body segments</td></tr><tr><td>TV-LE</td><td>Total volume of lower extremities (apex trochanter major to ankle joint)</td></tr><tr><td>TV-TR</td><td>Total volume of trunk (acromion to apex of trochanter major)</td></tr><tr><td>TV-UE</td><td>Total volume of upper extremities (wrist to acromion level)</td></tr><tr><td>LT-LE</td><td>Lean tissue volume of lower extremities (apex trochanter major to ankle joint)</td></tr><tr><td>LT-TR</td><td>Lean soft tissue volume of trunk (acromion to apex of trochanter major)</td></tr><tr><td>LT-UE</td><td>Lean soft tissue volume of upper extremities (wrist to acromion level)</td></tr><tr><td>SAST-LE</td><td>Adipose soft tissue volume of lower extremities (apex trochanter major to ankle joint)</td></tr><tr><td>SAST-TR</td><td>Adipose soft tissue volume of trunk (acromion to apex of trochanter major)</td></tr><tr><td>SAST-UE</td><td>Adipose soft tissue volume of upper extremities (wrist to acromion level)</td></tr></table> |
7ef8b9e36c2ec0a1439ebec6b7d5c3e53350c1a0d640ccfeca5bebf2dbb9eceb.png | simple | <table><tr><td>PSQI components score</td><td>Cases<i>n </i>= 314</td><td>Controls<i>n </i>= 102</td><td><i>P </i>value</td></tr><tr><td>Subjective sleep quality</td><td>1.01 ± 0.77</td><td>0.89 ± 0.79</td><td>0.127</td></tr><tr><td>Sleep latency</td><td>0.98 ± 0.89</td><td>0.69 ± 0.88</td><td>0.001</td></tr><tr><td>Sleep duration</td><td>0.68 ± 0.79</td><td>1.29 ± 0.86</td><td>0.000</td></tr><tr><td>Habitual sleep efficiency</td><td>0.95 ± 1.03</td><td>0.25 ± 0.64</td><td>0.000</td></tr><tr><td>Sleep disorders</td><td>1.21 ± 0.69</td><td>0.74 ± 0.63</td><td>0.000</td></tr><tr><td>Use of sleep medications</td><td>0.10 ± 0.46</td><td>0.01 ± 0.09</td><td>0.055</td></tr><tr><td>Daytime dysfunction</td><td>1.69 ± 0.95</td><td>1.63 ± 1.00</td><td>0.635</td></tr><tr><td>Total</td><td>6.62 ± 3.62</td><td>5.50 ± 2.51</td><td>0.020</td></tr></table> |
c55f82ada9b229c36431c9b181f335e42998fc3b71b4ee30baf811df505e5858.png | complex | <table><tr><td colspan="2"></td><td>Cd</td><td>As</td><td>Sb</td><td>Pb</td><td>Mn</td></tr><tr><td rowspan="2">LY(<i>n</i> = 6)</td><td>Mean ± SD</td><td>0.050 ± 0.001</td><td>26.495 ± 3 .2326</td><td>16.362 ± 1.458</td><td>30.337 ± 0.845</td><td>332.604 ± 3.662</td></tr><tr><td>Range</td><td>0.006–0.107</td><td>17.690–34.102</td><td>10.110–22.300</td><td>17.345–41.450</td><td>241.030–401.260</td></tr><tr><td rowspan="2">HY(<i>n</i> = 28)</td><td>Mean ± SD</td><td>0.865 ± 0.052</td><td>142.714 ± 2.210</td><td>20.393 ± 1.577</td><td>356.161 ± 1.905</td><td>420.316 ± 8.631</td></tr><tr><td>Range</td><td>0.345–1.451</td><td>26.870–562.340</td><td>9.620–36.400</td><td>124.360–756.200</td><td>215.630–666.310</td></tr><tr><td rowspan="2">LSJ(<i>n</i> = 20)</td><td>Mean ± SD</td><td>0.049 ± 0.001</td><td>32.628 ± 1.242</td><td>65.737 ± 5.340</td><td>13.732 ± 1.616</td><td>229.395 ± 7.921</td></tr><tr><td>Range</td><td>0.010–0.130</td><td>12.540–70.230</td><td>37.100–111.240</td><td>0.555–33.405</td><td>102.650–412.860</td></tr><tr><td rowspan="2">Total</td><td>Mean ± SD</td><td>0.472 ± 0.194</td><td>89.029 ± 1.461</td><td>36.739 ± 7.223</td><td>193.133 ± 3.855</td><td>339.996 ± 15.924</td></tr><tr><td>Range</td><td>0.006–1.451</td><td>12.540–562.340</td><td>9.620–111.240</td><td>0.555–756.200</td><td>102.650–666.310</td></tr><tr><td colspan="2">Background value<sup>a</sup></td><td>0.098</td><td>14</td><td></td><td>27</td><td>459</td></tr><tr><td colspan="2">MAC<sup>b</sup></td><td>0.3</td><td>25</td><td>36<sup>d</sup></td><td>300</td><td>NV<sup>c</sup></td></tr></table> |
df88d8c392d30b30c88e5600eeee3fc384b8e91b5c3104b8768f6422c3b62ad3.png | simple | <table><tr><td>Dataset</td><td></td><td>SparseAssembler</td><td>Gossamer</td><td>Minia</td><td>SGA</td><td>Diginorm-Velvet</td><td>DiMA</td><td>ZeMA</td></tr><tr><td><i>S. aureus</i></td><td>Amazon Instance/Cost ($)</td><td>M1/0</td><td>M2/0.015</td><td>M1/0</td><td>M2/0.17</td><td>M2/0.008</td><td>M2/0.006</td><td>M1/0</td></tr><tr><td></td><td>Amazon Time(min:sec)</td><td>24:20</td><td>7:45</td><td>5:46</td><td>82:23</td><td>3:50</td><td>3:8</td><td>20:30</td></tr><tr><td></td><td>Local Time (min:sec)</td><td>2:32</td><td>4:52</td><td>0:52</td><td>33:29</td><td>3:14</td><td>3:10</td><td>3:20</td></tr><tr><td><i>R. sphaeroides</i></td><td>Amazon Instance / Cost ($)</td><td>M1/0</td><td>M2/0.027</td><td>M1/0</td><td>M2/0.22</td><td>M2/0.011</td><td>M2/0.011</td><td>M1/0</td></tr><tr><td></td><td>Amazon Time (min:sec)</td><td>29:29</td><td>13:41</td><td>10:23</td><td>109:16</td><td>5:28</td><td>5:33</td><td>28:27</td></tr><tr><td></td><td>Local Time (min:sec)</td><td>3:15</td><td>7:37</td><td>1:24</td><td>55:37</td><td>5:12</td><td>5:15</td><td>6:4</td></tr><tr><td><i>Human chr 14</i></td><td>Amazon Instance/Cost ($)</td><td>M2/0.21</td><td>M2/0.59</td><td>M2/0.41</td><td></td><td>M2/0.16</td><td>M3/1.1</td><td>M2/0.17</td></tr><tr><td></td><td>Amazon Time (h:m:s)</td><td>1:45:32</td><td>4:57:12</td><td>3:22:27</td><td>Failed</td><td>1:18:21</td><td>1:23:23</td><td>1:23:22</td></tr><tr><td></td><td>Local Time (h:m:s)</td><td>1:1:37</td><td>3:6:50</td><td>1:33:13</td><td></td><td>1:18:16</td><td>1:21:8</td><td>1:15:09</td></tr><tr><td><i>B. impatiens</i></td><td>Amazon Instance / Cost ($)</td><td>M3/10.9</td><td></td><td>M2/7.24</td><td></td><td>M3/6.14</td><td>M3/6.04</td><td>M2/0.93</td></tr><tr><td></td><td>Amazon Time (h:m:s)</td><td>13:38:23</td><td>Failed</td><td>60:20:16</td><td>Failed</td><td>7:40:16</td><td>7:33:15</td><td>7:47:42</td></tr><tr><td></td><td>Local Time (h:m:s)</td><td>13:30:22</td><td></td><td>48:42:50</td><td></td><td>7:40:31</td><td>7:32:41</td><td>7:13:36</td></tr></table> |
21d3a7b301e7529aa119eb1ba073c4b7097ca21c087ae2ee9cdd945f0f7c8bd1.png | simple | <table><tr><td></td><td></td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td>6</td><td>7</td></tr><tr><td>1</td><td>PCS</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>2</td><td>MCS</td><td>-.051</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>3</td><td>Gender</td><td>-.147</td><td>-.075</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>4</td><td>Relationship with advisor</td><td>.135</td><td>.390**</td><td>-.084</td><td></td><td></td><td></td><td></td></tr><tr><td>5</td><td>Marital Status</td><td>.149</td><td>-.17</td><td>-.070</td><td>-.005</td><td></td><td></td><td></td></tr><tr><td>6</td><td>Perceived Stress</td><td>-.189*</td><td>-.642**</td><td>.169</td><td>-.315**</td><td>.073</td><td></td><td></td></tr><tr><td>7</td><td>Acculturative Stress</td><td>-.362**</td><td>-.442**</td><td>.054</td><td>-.333**</td><td>-.109</td><td>.463**</td><td></td></tr></table> |
3f8faa6cbc38fb04d2d050c34beb39809d701d10f75828191a80cd9c73f6d5be.png | complex | <table><tr><td rowspan="2">Item</td><td>Case group (<i>n</i> = 30)</td><td colspan="2">Control group (<i>n</i> = 90)</td><td colspan="2">Iranian general population (<i>n</i> = 1997)</td></tr><tr><td>Mean ± SD</td><td>Mean ± SD</td><td><i>P</i> value*</td><td>Mean ± SD</td><td><i>P</i> value*</td></tr><tr><td>Physical functioning (PF)</td><td>42.20 ± 23.11</td><td>42.83 ± 22.31</td><td>0.949</td><td>85.3 ± 20.8</td><td>< 0.001</td></tr><tr><td>Role physical (RP)</td><td>15.83 ± 23.20</td><td>25.00 ± 33.10</td><td>0.292</td><td>70.0 ± 38.0</td><td>< 0.001</td></tr><tr><td>Bodily pain (BP)</td><td>24.42 ± 23.83</td><td>24.08 ± 18.80</td><td>0.874</td><td>79.4 ± 25.1</td><td>< 0.001</td></tr><tr><td>General health (GH)</td><td>34.00 ± 20.53</td><td>33.50 ± 19.24</td><td>0.362</td><td>67.5 ± 20.4</td><td>< 0.001</td></tr><tr><td>Vitality (VT)</td><td>44.67 ± 21.99</td><td>49.83 ± 20.21</td><td>0.261</td><td>65.8 ± 17.3</td><td>< 0.001</td></tr><tr><td>Social functioning (SF)</td><td>41.25 ± 27.49</td><td>47.36 ± 26.20</td><td>0.244</td><td>76.0 ± 24.4</td><td>< 0.001</td></tr><tr><td>Role emotional (RE)</td><td>18.89 ± 32.38</td><td>36.67 ± 43.00</td><td>0.050</td><td>65.6 ± 41.4</td><td>< 0.001</td></tr><tr><td>Mental health (MH)</td><td>46.53 ± 25.59</td><td>50.93 ± 19.71</td><td>0.362</td><td>67.0 ± 18.0</td><td>< 0.001</td></tr><tr><td>PCS</td><td>29.10 ± 15.77</td><td>31.35 ± 16.00</td><td>0.503</td><td>–</td><td>–</td></tr><tr><td>MCS</td><td>37.83 ± 21.50</td><td>46.20 ± 20.40</td><td>0.025</td><td>–</td><td>–</td></tr></table> |
e537288e4ec938669e19bbf01e812357c9e961fddde546206f5946eee010a18b.png | simple | <table><tr><td>Method</td><td><i>X</i><sub>1</sub> (mm)</td><td><i>X</i><sub>2</sub> (mm)</td><td><i>X</i><sub>3</sub> (mm)</td><td><i>M</i> (kg)</td></tr><tr><td>Original</td><td>4</td><td>20</td><td>7</td><td>39.8140</td></tr><tr><td>GA</td><td>4.8182</td><td>14.0024</td><td>3.0029</td><td>31.9826</td></tr><tr><td>BMPSO</td><td>4.8185</td><td>14.0001</td><td>3.0017</td><td>31.3458</td></tr></table> |
c6b8583ae2023338c2c176fbe2df63f5e1db6c735f83769ba9c793e614feffa4.png | simple | <table><tr><td>Gene/exon</td><td>Sequences</td><td>T<sub>ann</sub></td></tr><tr><td>β-globin</td><td>Forward primer: 5'-GTGCACCTGACTCCTGAGGAGA-3'Reverse primer: 5'-CCTTGATACCAACCTGCCCAG-3'Probe: 5'-<i>FAM</i>-AAGGTGAACGTGGATGAAGTTGGTGG-<i>RTQ1-3'</i></td><td>60°C</td></tr><tr><td>PARK2\ex1</td><td>Forward primer: 5'-CAGCGGCTCTCCTGGGTTAAA-3'Reverse primer: 5'-TACGACTCCCAGCAGGCCCT-3'Probe: 5'-<i>ROX</i>-CCTAGGAATGCGCACGCGCGGAG-<i>RTQ1-</i>3'</td><td>60°C</td></tr><tr><td>PARK2\ex2</td><td>Forward primer: 5'-ATCTCAGGCATGAATGTCAGATT-3'Reverse primer: 5'-TGACCAGTTGCGTGTGATTT-3'Probe: 5'-<i>ROX</i>-ATGAGCAATGGAGCTGGCGGCATCC-<i>RTQ1</i>-3'</td><td>60°C</td></tr><tr><td>PARK2\ex3</td><td>Forward primer: 5'-CATTGTGCAGAGACCGTGGAGAA-3'Reverse primer: 5'-GCTGAGGTCCACCCGAGTCAA-3'Probe: 5'-<i>ROX</i>-AAATGAATGCAACTGGAGGCGACGACCC-<i>RTQ1</i>-3'</td><td>60°C</td></tr><tr><td>PARK2\ex4</td><td>Forward primer: 5'-TAGCCACTTCTTCTGCTTTT-3'Reverse primer: 5'-TGCACTGTACCCTGAGTTTT-3'Probe: 5'-<i>ROX</i>-ATTGCAAAGGCCCCTGTCAAAGAGTGCA-<i>RTQ1</i>-3'</td><td>60°C</td></tr><tr><td>PARK2\ex5</td><td>Forward primer: 5'-TCTTGCTGGGATGATGTTTTAATTCCAAA-3'Reverse primer: 5'-TTGCAATAAGAGGAATGAAT-3'Probe: 5'-<i>ROX</i>-AATGCCAATCCCCACACTGCCCTGG-<i>RTQ1</i>-3'</td><td>60°C</td></tr><tr><td>PARK2\ex6</td><td>Forward primer: 5'-CCGTGGAGGGAAGTGACACTAT-3'Reverse primer: 5'-TGCACCTGATCGCAACAAAT-3'Probe: 5'-<i>ROX</i>-TGTGCGCGTAATGCAAGTGATGTTCCG-<i>RTQ1</i>-3'</td><td>60°C</td></tr><tr><td>PARK2\ex7</td><td>Forward primer: 5'-GGGTCGTGAACAAACTGCCGATCATT-3'Reverse primer: 5'-AGGAGCCCCGTCCTGGTTTT-3'Probe: 5'-<i>ROX-</i>AAGCAAATCACGTGGCGGGAGTTGCAC-<i>RTQ1-</i>3'</td><td>60°C</td></tr><tr><td>PARK2\ex8</td><td>Forward primer: 5'-TCACTCACCTGCTCTTCTCCCAGAAT-3'Reverse primer: 5'-CAGAGTGAAAGTGACGTTTT-3'Probe: 5'-<i>ROX-</i>TCAAGGAGTTGGGACAGCCAGCTGTTGG-<i>RTQ1</i>-3'</td><td>60°C</td></tr><tr><td>PARK2\ex9</td><td>Forward primer: 5'-ACCCCACAGCCCAGGCCATT-3'Reverse primer: 5'-TGCAGATGGGGGGCGTGTTA-3'Probe: 5'-<i>ROX-</i>TTCGCAGGTGACTTTCCTCTGGTCAGGC-<i>RTQ1-</i>3'</td><td>60°C</td></tr><tr><td>PARK2\ex10</td><td>Forward primer: 5'-GCTTGGAGGAATGAGTAGGGCATT-3'Reverse primer: 5'-GTTTGCCTTCTGCCGGGAAT-3'Probe: 5'-<i>ROX-</i>AGGCTTCAAATACGGCACTGCACTCCCC-<i>RTQ1-</i>3'</td><td>60°C</td></tr><tr><td>PARK2\ex11</td><td>Forward primer: 5'-TGGTGGTTTTCTTGATGGTTT-3'Reverse primer: 5'-AACGCCTTTCCTCTTTGTTT-3'Probe: 5'-<i>ROX-</i>TCGGCGGCTCTTTCATCGACTCTGTAGG-<i>RTQ1</i>-3'</td><td>60°C</td></tr><tr><td>PARK2\ex12</td><td>Forward primer: 5'-CACGATCTTCCTGAGAAGTCAGACAAT-3'Reverse primer: 5'-ACAACACTGCATGCGGCAAA-3'Probe: 5'-<i>ROX</i>-TCTGCGTAGTGTGGGTAAGAGCATGCGG-<i>RTQ1</i>-3'</td><td>60°C</td></tr></table> |
f7799f919238ec4e0f1e5e46fb67b84d0ec6e3f22b7edaccb1811d5b96e8ed7b.png | simple | <table><tr><td></td><td>SCS</td><td>CCS</td><td>TCS</td></tr><tr><td>Log evidence</td><td>14084</td><td>14072</td><td>14058</td></tr></table> |
1aeab85d7f738b19b7ee9e7c334e078b62ccff2a70d197dc2aeeed8776bab258.png | complex | <table><tr><td rowspan="2">Cell line</td><td rowspan="2">EGFR mutation status</td><td>Sulforaphane</td></tr><tr><td>IC50 (μM) <sup>a</sup></td></tr><tr><td>A549</td><td>Wild-type</td><td>10.2 ± 0.15</td></tr><tr><td>CL1-5</td><td>Wild-type</td><td>9.7 ± 0.33</td></tr><tr><td>H3255</td><td>L858R <sup>b</sup></td><td>14.5 ± 0.21</td></tr><tr><td>PC9/gef <sup>c</sup></td><td>Exon 19 del.</td><td>7.3 ± 0.25</td></tr><tr><td>H1975</td><td>L858R/T790M <sup>d</sup></td><td>5.9 ± 0.18</td></tr><tr><td>HFB</td><td>Wild-type</td><td>65.4 ± 0.29</td></tr></table> |
9ea605bdf32867968f95397ab97b532e6ee8c2dfbfea9461c710a17f4254325f.png | simple | <table><tr><td>Gene</td><td>Length</td><td>Forward Sequence (5′>3′)</td><td>Reverse Sequence (5′>3′)</td></tr><tr><td><i>Runx2</i></td><td>250 bp</td><td>CCACCACTCACTACCACACG</td><td>TCAGCGTCAACACCATCATT</td></tr><tr><td><i>Osterix</i></td><td>373 bp</td><td>ACCAGGTCCAGGCAACACACCTAC</td><td>GCAGTCGCAGGTAGAACGCCCTGC</td></tr><tr><td><i>BMP2</i></td><td>154 bp</td><td>GGGACCCGCTGTCTTCTAGT</td><td>TCAACTCAAATTCGCTGAGGAC</td></tr><tr><td><i>Osteocalcin</i></td><td>302 bp</td><td>AGACAAGTCCCACACAGCAG</td><td>GGCGGTCTTCAAGCCATACT</td></tr><tr><td><i>Bone sialoproiten</i></td><td>312 bp</td><td>CTGAAGCAGGTGCAGAAGGA</td><td>TCTGACCCTCGTAGCCTTCA</td></tr><tr><td><i>Osteopontin</i></td><td>354 bp</td><td>CTGGCAGCTCAGAGGAGAAG</td><td>GGACATCGACTGTAGGGACG</td></tr><tr><td><i>ALP</i></td><td>211 bp</td><td>TAACACCAACGCTCAGGTCC</td><td>GTGGTTCACCCGAGTGGTAG</td></tr><tr><td><i>Smad1</i></td><td>97 bp</td><td>ACCTGTGGCTTCCGTCTC</td><td>ATCGTGGCTCCTTCGTC</td></tr><tr><td><i>Smad4</i></td><td>145 bp</td><td>CAGCACTACCACCTGGACTGGA</td><td>CTGGAATGCAAGCTCATTGTGAA</td></tr><tr><td><i>Smad5</i></td><td>197 bp</td><td>AAGTAGATTCTGCCTGGGATT</td><td>AGACGGTGGTGGGATGG</td></tr><tr><td><i>Smad8</i></td><td>169 bp</td><td>ATCCCTGGCAATCTGTA</td><td>CCCTGGCTGTCCTGTAA</td></tr><tr><td><i>PARP-1</i></td><td>72 bp</td><td>GGAAAGGGATCTACTTTGCCG</td><td>TCGGGTCTCCCTGAGATGTG</td></tr><tr><td><i>GAPDH</i></td><td>240 bp</td><td>TGATGACATCAAGAAGGTGGTGAAG</td><td>TCCTTGGAGGCCATGTAGGCCAT</td></tr></table> |
0e86beebf12e6549fd16c43d3cd999cd2d605adf8251db0ff247fffcd83707a7.png | complex | <table><tr><td>Characteristics</td><td>Number</td><td>Percentage</td></tr><tr><td colspan="3">Socio-demographic characteristics</td></tr><tr><td colspan="3">Gender (n = 674)</td></tr><tr><td>Male</td><td>278</td><td>41%</td></tr><tr><td>Female</td><td>396</td><td>59%</td></tr><tr><td colspan="3">Marital status (n = 679)</td></tr><tr><td>Married</td><td>232</td><td>34%</td></tr><tr><td>Single</td><td>447</td><td>65%</td></tr><tr><td colspan="3">Race (n = 685)</td></tr><tr><td>Black</td><td>160</td><td>23%</td></tr><tr><td>Indian</td><td>143</td><td>21%</td></tr><tr><td>White</td><td>319</td><td>47%</td></tr><tr><td>Coloured</td><td>53</td><td>8%</td></tr><tr><td colspan="3">Medical school characteristics</td></tr><tr><td colspan="3">Profession (n = 654)</td></tr><tr><td>Medical doctor</td><td>544</td><td>79%</td></tr><tr><td>Dental practitioner</td><td>110</td><td>16%</td></tr><tr><td colspan="3">Tertiary institution (n = 677)</td></tr><tr><td>University of Cape Town</td><td>73</td><td>11%</td></tr><tr><td>University of the Witwatersrand</td><td>84</td><td>12%</td></tr><tr><td>University of KwaZulu-Natal</td><td>101</td><td>15%</td></tr><tr><td>University of Limpopo</td><td>55</td><td>8%</td></tr><tr><td>University of the Free State</td><td>64</td><td>9%</td></tr><tr><td>University of Pretoria</td><td>101</td><td>15%</td></tr><tr><td>University of the Western Cape</td><td>64</td><td>9%</td></tr><tr><td>Stellenbosch University</td><td>101</td><td>15%</td></tr><tr><td>Walter Sisulu University</td><td>34</td><td>5%</td></tr><tr><td>Provincial bursary obligation (versus not) (n = 670)</td><td>142</td><td>21%</td></tr><tr><td>Student loans (versus not) (n = 678)</td><td>142</td><td>35%</td></tr></table> |
d802566df934405f5ef6f042cacc9d920cb7ce9539db42fb263623320bd4f901.png | simple | <table><tr><td>Number of donors</td><td>Europe</td><td>North America</td><td>Australasia and South Africa</td><td>Total</td></tr><tr><td><50</td><td>7</td><td>2</td><td>5</td><td>14</td></tr><tr><td>51–100</td><td>2</td><td>1</td><td>2</td><td>5</td></tr><tr><td>101–1000</td><td>2</td><td>0</td><td>0</td><td>2</td></tr><tr><td>>1000</td><td>0</td><td>2</td><td>0</td><td>2</td></tr></table> |
c4d0737081f98a9d10f4d225a8824e15ffc0bc050581599ee26d8401c736c8ad.png | simple | <table><tr><td>Model description</td><td>RMSEA</td><td>CFI</td><td><i>χ</i><sup>2</sup></td><td>df</td><td>Δχ<sup>2</sup></td><td>Δdf</td><td>Statistical significance</td></tr><tr><td>1. Configural model: no constraints imposed</td><td>0.02</td><td>0.99</td><td>8.06</td><td>6</td><td>-</td><td>-</td><td>-</td></tr><tr><td>2. Factor loadings: constrained equally across groups</td><td>0.03</td><td>0.97</td><td>45.44</td><td>19</td><td>37.38</td><td>13</td><td>p < 0.0005</td></tr></table> |
b9bd318cd456fa6b58b76b407e996998b4d51e9561b2ab47ceaf1dfbed241471.png | complex | <table><tr><td colspan="2">Before treatment compared to first treatment (PET 1–PET 2)</td></tr><tr><td>ACC</td><td>Midbrain (+0.45), pallidum (+0.61), putamen (+0.34)</td></tr><tr><td>Hippocampus</td><td>Amygdala (+0.20), insula (+0.37), pallidum (+0.47)</td></tr><tr><td>Insula</td><td>Pallidum (+0.56)</td></tr></table> |
e24f42a303dd97e56eb4633d80b45f7ba3f31cf917df0b8ae572aef028a13f6f.png | complex | <table><tr><td></td><td colspan="2">Group OP vs. Group 0T</td><td colspan="2">Group NT vs. Group NP</td></tr><tr><td></td><td>T = 4 weeks</td><td>T = 8 weeks</td><td>T = 4 weeks</td><td>T = 8 weeks</td></tr><tr><td>Weight</td><td>p < 0.01</td><td>p < 0.001</td><td>p < 0.05</td><td>p < 0.01</td></tr><tr><td>BMI</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td></tr><tr><td>Cholesterol</td><td>p < 0.001</td><td>NS</td><td>NS</td><td>NS</td></tr><tr><td>HDL</td><td>NS</td><td>p < 0.001</td><td>p < 0.05</td><td>p < 0.05</td></tr><tr><td>LDL</td><td>NS</td><td>p < 0.01</td><td>NS</td><td>p < 0.01</td></tr><tr><td>Triglycerides</td><td>NS</td><td>p < 0.001</td><td>p < 0.01</td><td>p < 0.01</td></tr><tr><td>Systolic BP</td><td>NS</td><td>p < 0.05</td><td>p < 0.05</td><td>NS</td></tr><tr><td>Diastolic BP</td><td>p < 0.05</td><td>p < 0.001</td><td>p < 0.05</td><td>p < 0.001</td></tr><tr><td>Glucose</td><td>p < 0.001</td><td>p < 0.001</td><td>NS</td><td>NS</td></tr></table> |
82b86358adbe347fe59606f6ab5b825eef5dfc208ade3802586845d6398f2aca.png | complex | <table><tr><td></td><td colspan="3">Derivation cohort</td><td></td><td>All cohorts</td><td></td></tr><tr><td>PEARL indices</td><td>B</td><td>p Value</td><td>OR (95% CI)</td><td>Weighting</td><td>B</td><td>Updated weighting</td></tr><tr><td>Previous admissions (2+)</td><td>1.04</td><td><0.001</td><td>2.84 (1.98 to 4.07)</td><td>2</td><td>1.14</td><td>3</td></tr><tr><td>eMRCD score 4</td><td>0.67</td><td>0.002</td><td>1.96 (1.29 to 2.98)</td><td>1</td><td>0.37</td><td>1</td></tr><tr><td>eMRCD score 5a</td><td>1.13</td><td><0.001</td><td>3.10 (1.89 to 5.10)</td><td>2</td><td>0.85</td><td>2</td></tr><tr><td>eMRCD score 5b</td><td>2.02</td><td><0.001</td><td>7.51 (4.17 to 13.52)</td><td>3</td><td>1.09</td><td>3</td></tr><tr><td>Age 80 or more</td><td>0.38</td><td>0.032</td><td>1.47 (1.03 to 2.08)</td><td>1</td><td>0.38</td><td>1</td></tr><tr><td>Right ventricular failure</td><td>0.50</td><td>0.050</td><td>1.66 (1.00 to 2.74)</td><td>1</td><td>0.63</td><td>1</td></tr><tr><td>Left ventricular failure</td><td>0.52</td><td>0.080</td><td>1.68 (0.94 to 3.00)</td><td>1</td><td>0.52</td><td>1</td></tr><tr><td>Constant</td><td>−0.78</td><td><0.001</td><td>0.46 (0.36 to 0.58)</td><td></td><td>−0.95</td><td></td></tr><tr><td colspan="6">Maximum PEARL score</td><td>9</td></tr></table> |
8ca7b4c7f23cbd5a9f8614f8576e4fbf575db7b64ed73b40bdb87899888af7c8.png | simple | <table><tr><td></td><td>Migration of stem</td><td>Rotation of stem</td></tr><tr><td></td><td>(mm)</td><td>(degrees)</td></tr><tr><td>x-axis</td><td>0.09</td><td>0.36</td></tr><tr><td>y-axis</td><td>0.13</td><td>0.76</td></tr><tr><td>z-axis</td><td>0.23</td><td>0.13</td></tr></table> |
b07fb1dad3a660609a43b21e70e84b328172be31506b72d6cfc31da7e77e13d9.png | complex | <table><tr><td></td><td colspan="8">IC<sub>50 </sub>(μM)</td></tr><tr><td>Tumor type Cell lines</td><td colspan="3">Rhabdoid</td><td colspan="3">Glioma</td><td colspan="2">Breast</td></tr><tr><td></td><td>MON</td><td>G401</td><td>A204</td><td>SF268</td><td>U87</td><td>U251</td><td>MCF7</td><td>MDAMB231</td></tr><tr><td>ATRA</td><td>> 50</td><td>> 50</td><td>> 50</td><td>> 50</td><td>> 50</td><td>> 50</td><td>> 50</td><td>> 50</td></tr><tr><td>4-HPR</td><td>2.2</td><td>0.1</td><td>2.0</td><td>6.9</td><td>5.0</td><td>1.4</td><td>2.2</td><td>0.4</td></tr><tr><td>5h</td><td>3.6</td><td>0.3</td><td>1.7</td><td>18.9</td><td>16.3</td><td>5.8</td><td>6.3</td><td>N/A*</td></tr><tr><td>5j</td><td>1.2</td><td>3.0</td><td>8.2</td><td>12.0</td><td>13.7</td><td>9.1</td><td>11.8</td><td>23</td></tr><tr><td>11a</td><td>1.9</td><td>0.2</td><td>4.4</td><td>10.4</td><td>5.0</td><td>2.4</td><td>8.3</td><td>2.3</td></tr><tr><td>11c</td><td>5.2</td><td>0.3</td><td>5.6</td><td>15.7</td><td>9.3</td><td>5.9</td><td>12.1</td><td>5.3</td></tr><tr><td>11d</td><td>1.3</td><td>3.2</td><td>7.5</td><td>3.8</td><td>9.4</td><td>7.8</td><td>8.2</td><td>12.0</td></tr></table> |
260e7cc7204a1ca7412b8f2bfc93642736e6bd82e7a0f16d95a9e33c049f3974.png | simple | <table><tr><td>Stratum</td><td>LD</td><td>Special education </td><td>ADHD</td></tr><tr><td>Study population</td><td></td><td>1.51 (1.14, 2.00)</td><td></td><td>1.44 (1.03, 2.01)</td><td></td><td>0.84 (0.61, 1.16)</td></tr><tr><td>Below median lead</td><td></td><td>1.67 (1.09, 2.56)</td><td></td><td>1.74 (0.91, 3.30)</td><td></td><td>1.11 (0.65, 1.91)</td></tr><tr><td>Above median lead</td><td></td><td>1.39 (0.98, 1.95)</td><td></td><td>1.29 (0.83, 2.01)</td><td></td><td>0.73 (0.52, 1.03)</td></tr><tr><td>Female</td><td></td><td>1.24 (0.75, 2.04)</td><td></td><td>1.31 (0.81, 2.13)</td><td></td><td>0.91 (0.50, 1.69)</td></tr><tr><td>Male</td><td></td><td>1.75 (1.24, 2.46)</td><td></td><td>1.73 (1.02, 2.92)</td><td></td><td>0.79 (0.56, 1.11)</td></tr></table> |
8d441579ca9c4ce59d9089e9db3683ba6e20a18774d0ecb25ea392e301a6b39a.png | simple | <table><tr><td>Protein name</td><td>Accession</td><td>Score</td><td>Coverage</td><td>Peptide</td><td>Fold change</td></tr><tr><td>Upregulated proteins</td></tr><tr><td>Sarcoplasmic calcium-binding protein 1</td><td>comp40442_c0_seq1_No.1</td><td>83</td><td>16.1</td><td>3</td><td>8.40</td></tr><tr><td>Troponin C isoform 2b</td><td>comp22592_c0_seq1_No.1</td><td>69</td><td>26.3</td><td>3</td><td>2.78</td></tr><tr><td>Clip domain serine proteinase 3</td><td>comp19522_c0_seq1_No.1</td><td>520</td><td>33.8</td><td>9</td><td>2.40</td></tr><tr><td>Copine-8</td><td>comp20718_c0_seq2_No.1</td><td>841</td><td>30.9</td><td>14</td><td>2.19</td></tr><tr><td>Slow muscle myosin S1 heavy chain</td><td>comp20546_c0_seq16_No.1</td><td>2,058</td><td>43.7</td><td>26</td><td>2.13</td></tr><tr><td>Putative secreted salivary gland peptide</td><td>comp12272_c1_seq1_No.1</td><td>83</td><td>22</td><td>3</td><td>2.23</td></tr><tr><td>Chloride intracellular Channel isoform 1</td><td>comp20820_c0_seq1_No.1</td><td>100</td><td>25.7</td><td>5</td><td>2.11</td></tr><tr><td>Myophilin</td><td>comp18304_c1_seq2_No.1</td><td>1,662</td><td>62.4</td><td>8</td><td>2.03</td></tr><tr><td>Spermine synthase</td><td>comp18763_c0_seq1_No.1</td><td>200</td><td>16.1</td><td>4</td><td>2.02</td></tr><tr><td>Putative phosphoglycerate kinase</td><td>comp12041_c0_seq1_No.1</td><td>897</td><td>33.5</td><td>13</td><td>2.02</td></tr><tr><td>Downregulated proteins</td></tr><tr><td>Sacsin</td><td>comp19443_c0_seq1_No.1</td><td>42</td><td>0.2</td><td>1</td><td>31.39</td></tr><tr><td>Phospholipase D1</td><td>comp1157_c0_seq1_No.1</td><td>211</td><td>17.4</td><td>5</td><td>6.97</td></tr><tr><td>Low-density lipoprotein receptor</td><td>comp20609_c0_seq1_No.1</td><td>283</td><td>10.2</td><td>6</td><td>5.77</td></tr><tr><td><i>Pseudomonas aeruginosa</i> pathogenicity island I</td><td>comp20408_c0_seq1_No.1</td><td>54</td><td>7.6</td><td>1</td><td>3.02</td></tr><tr><td>pacifastin-like serine protease inhibitor</td><td>comp3991_c0_seq1_No.1</td><td>82</td><td>15.1</td><td>2</td><td>2.99</td></tr><tr><td>Anti-lipopolysaccharide factor 4</td><td>comp12264_c0_seq1_No.1</td><td>179</td><td>27.6</td><td>2</td><td>2.82</td></tr><tr><td>Anti-lipopolysaccharide factor isoform 4</td><td>comp20686_c1_seq1_No.1</td><td>126</td><td>47.7</td><td>4</td><td>2.12</td></tr></table> |
5eab6aeba50267f8ad35d7fd5815f640591d694756b91097d3afbcc8d243c8da.png | simple | <table><tr><td>Gene</td><td>% Nucleotide identity</td><td>% Amino-acid identity</td></tr><tr><td>NP</td><td>98.9</td><td>99.3</td></tr><tr><td>P</td><td>98.8</td><td>98.4</td></tr><tr><td>M</td><td>98.5</td><td>98.7</td></tr><tr><td>G</td><td>98.2</td><td>98.4</td></tr><tr><td>L</td><td>99.0</td><td>99.8</td></tr></table> |
2395f47a9a96a9e837e21cbe3b3000dc2daeaeca418ebc88994fd1d3a4740eaf.png | simple | <table><tr><td>Test</td><td>Method description</td></tr><tr><td>Polyacrylamide gel electrophoresis (reducing and non-reducing)</td><td>Polyacrylamide gel electrophoresis performed in the presence of sodium dodecyl sulphate (SDS PAGE) under both reducing and non-reducing conditions. Gels were stained using Colloidal Coomassie Blue staining</td></tr><tr><td>Size exclusion chromatography</td><td>Resolution of aggregated forms from the monomeric form of rFIXFc using high performance liquid chromatography (TSK<sub>gel</sub>G3000SW<sub>XL</sub> column)</td></tr><tr><td>Coagulation activity</td><td>One-stage aPTT method performed in accordance with Pharmacopeia guidelines (USP<32> and Ph.Eur. 2.7.11) with respect to WHO International Standard for Factor IX concentrate</td></tr><tr><td>FcRn binding</td><td>FcRn competitive binding measured using an amplified luminescent proximity homogenous assay</td></tr><tr><td>Activated rFIXFc</td><td>Enzyme-linked immunosorbent assay (ELISA) based on the binding of hATIII to activated factor IX for the detection of the activated form of rFIXFc</td></tr><tr><td>Bioburden</td><td>Microbial enumeration test performed in accordance with Pharmacopeia guidelines (USP<61> and Ph.Eur. 2.6.12)</td></tr><tr><td>Endotoxin</td><td>Kinetic turbidimetric method in accordance with Pharmacopeia guidelines (USP<85> and Ph. Eur. 2.6.14)</td></tr></table> |
c4dd3b46d6a0947fbc3bd78c458c8197af07b49ef8fc5553f1d7d4bde0a76d4c.png | complex | <table><tr><td rowspan="2" colspan="2">Haplotype *</td><td colspan="2">CAD</td><td colspan="2">BD</td><td rowspan="2">χ<sup>2</sup></td><td rowspan="2">OR (95% CI) Univariate Analysis</td><td rowspan="2"><i>p</i></td></tr><tr><td>+ (%)</td><td>− (%)</td><td>+ (%)</td><td>− (%)</td></tr><tr><td>H1</td><td>CT</td><td>1.2</td><td>98.8</td><td>0</td><td>100</td><td>5.18</td><td>2.04 (1.90–2.19) <i><sup>a</sup></i></td><td>0.014</td></tr><tr><td>H2</td><td>TT</td><td>28.8</td><td>71.2</td><td>32.7</td><td>67.3</td><td>1.50</td><td>0.83 (0.62–1.12)</td><td>0.22</td></tr><tr><td>H3</td><td>CC</td><td>41.5</td><td>58.5</td><td>41.0</td><td>59.0</td><td>0.02</td><td>1.02 (0.77–1.34)</td><td>0.89</td></tr><tr><td>H4</td><td>TC</td><td>28.5</td><td>71.5</td><td>26.3</td><td>73.7</td><td>0.52</td><td>1.12 (0.82–1.52)</td><td>0.47</td></tr></table> |
67d0af5eea5119508543774634321b63ff59758a7b183ee3ffa20f86a079fa54.png | simple | <table><tr><td>Membrane</td><td>C 1s (%)</td><td>O 1s (%)</td><td>Al 2p (%)</td><td>P 2s (%)</td><td>(O/Al)</td></tr><tr><td>Al-O<i>x</i></td><td>23.9</td><td>48.7</td><td>25.4</td><td>2.0</td><td>1.9</td></tr></table> |
553fa4b44cbbf6f97f394959962eea8bb05941b91b5652c1fad29fb379f6f518.png | simple | <table><tr><td></td><td>Mercury measure available</td><td>No mercury measure</td></tr><tr><td>4+ DAs at start of pregnancy</td><td>69.6% (1823)</td><td>69.9% (4200)</td></tr><tr><td>Visited dentist in pregnancy</td><td>86.3% (2464)</td><td>86.0% (5765)</td></tr><tr><td>Had a new DA in pregnancy</td><td>22.4% (633)</td><td>25.0% (1632)</td></tr><tr><td>Had old DA removed in pregnancy</td><td>14.8% (420)</td><td>15.7% (1021)</td></tr><tr><td>Tooth extraction in pregnancy</td><td>3.8% (108)</td><td>3.9% (251)</td></tr></table> |
770036b5a3b679157286de7f840a3a8efb5f04018000b23e22f04949e9a993ce.png | simple | <table><tr><td>Objectives/Social Values</td><td>Option which maximises likelihood of success</td></tr><tr><td>Equalise access, outcome</td><td>Universal (monopoly) Public Insurance/Financing</td></tr><tr><td>Maximise choice; diversity + safety netOptimise the max of these 2 objectives</td><td>Pure private (competitive) scheme</td></tr><tr><td>Both of the above</td><td>Mixed public-private scheme</td></tr></table> |
156a0d4d405c42cb141e5cb06ef1410fd2507e7b0440aa33459d8ecc7b6b20af.png | simple | <table><tr><td>Condition</td><td>Major reported impairments of postural responses</td><td>Cortical function during impaired standing postural responses</td></tr><tr><td>Stroke involving cortex</td><td>Feet-in-place responses: change in the distal-to-proximal muscle pattern and delayed muscle onset as well as delayed and slowed rates of force development in the more severely involved limb (Di Fabio et al., 1986; Ikai et al., 2003)</td><td>Unaware of studies utilizing measures of cortical neurophysiology during standing postural responses post-stroke</td></tr><tr><td></td><td>Stepping responses: paretic limb exhibits delayed foot-lift, low clearance, need for multiple steps, or an inability to initiate a step (Lakhani et al., 2011; Martinez et al., 2013). Steps are non-paretic limb dominant, even when obstacles block the limb (Lakhani et al., 2011; Mansfield et al., 2012). Impairments associate with increased fall risk and, in contrast, greater use of the paretic limb associates with better recovery (Mansfield et al., 2012, 2013)</td><td></td></tr><tr><td>Advanced age</td><td>Age associates with delays and antagonistic co-contraction of muscles, as well as greater displacement and instability (Halicka et al., 2012)</td><td>Electroencephalographic (EEG) PEP delayed, bifid (double-peaked), and decreased with age—effects larger in balance impaired elders (Duckrow et al., 1999)</td></tr><tr><td></td><td>Dual task costs greater for elderly only in late-phase in-place and stepping responses, more so for stepping and more so if balance impaired elder (Brown et al., 1999; Rankin et al., 2000; Brauer et al., 2001, 2002; Zettel et al., 2008)</td><td></td></tr><tr><td>Parkinson's disease</td><td>Falls, instability, antagonistic co-contraction and lack of modulation based on knowledge of perturbation. Stepping responses may exhibit freezing or have decreased velocity and step length (Jacobs et al., 2005, 2009b; Jacobs and Horak, 2006; Smith et al., 2012)</td><td>Increased desynchronization of EEG beta signal, and this increase associates with decreased response adaptation to perturbation magnitude (Smith et al., 2012)</td></tr><tr><td></td><td>With dual tasking, in-place responses are not modulated, and falls increase during stepping responses, but postural preparation or freezing unchanged (de Lima-Pardini et al., 2012; Jacobs et al., 2014a)</td><td></td></tr><tr><td>Low back pain</td><td>Increased pre-perturbation muscle activation, increased activation amplitude at distal muscle, but decreased or delayed trunk muscle activation (Jacobs et al., 2011)</td><td>Late positive peak PEP larger with LBP; larger PEP correlates with less postural instability, disability, and fear of activity (Jacobs et al., 2014b)</td></tr></table> |
acb3e3ad444b9ef0fb63c1dd0239bc3663bc73388509d0f2ca24820a342e71cf.png | complex | <table><tr><td rowspan="2"> </td><td colspan="3">PRE TTS implementation</td><td colspan="3">POST TTS implementation</td></tr><tr><td><i>Missed injuries</i></td><td><i>Study population (N)</i></td><td><i>Missed injury rate (%)</i></td><td><i>Patients with Missed injuries (N)</i></td><td><i>Study population (N)</i></td><td><i>Missed injury rate (%)</i></td></tr><tr><td>Enderson, 1990</td><td> </td><td>N/A</td><td>2.0</td><td>37</td><td>399</td><td>9.27</td></tr><tr><td>Vles, 2003</td><td> </td><td> </td><td> </td><td>49</td><td>3,879</td><td>1.26</td></tr><tr><td>Hoff, 2004</td><td> </td><td> </td><td> </td><td>42</td><td>432</td><td>9.72</td></tr><tr><td>Soundappan, 2004</td><td> </td><td> </td><td> </td><td>12</td><td>76</td><td>15.8</td></tr><tr><td>Howard, 2006</td><td> </td><td> </td><td> </td><td>12</td><td>90</td><td>13.3</td></tr><tr><td>Okello, 2007</td><td> </td><td> </td><td> </td><td>78</td><td>403</td><td>19.4</td></tr><tr><td>Janjua, 2008</td><td> </td><td> </td><td> </td><td>134</td><td>206</td><td>65.0</td></tr><tr><td>Ursic, 2009</td><td>35</td><td>981</td><td>3.57</td><td>62</td><td>1,006</td><td>6.16</td></tr><tr><td>Huynh, 2010</td><td> </td><td> </td><td> </td><td>80</td><td>5,143</td><td>1.56</td></tr><tr><td>Overall</td><td>35</td><td>981</td><td>3.57</td><td>506</td><td>11,634</td><td>4.35</td></tr></table> |
3d90d81ece25f1c879942ee985d0bae1e576e90974e44b9499561da533c2a62d.png | complex | <table><tr><td>Stress-associated and virulence genes</td><td>Protein encoded/function</td></tr><tr><td colspan="2">Oxidative stress</td></tr><tr><td><i>oxyR</i></td><td>DNA-binding transcriptional regulator OxyR</td></tr><tr><td><i>sodA</i></td><td>Manganese-containing superoxide dismutase</td></tr><tr><td><i>soxR</i></td><td>Redox-sensitive transcriptional activator of oxidative stress regulon</td></tr><tr><td colspan="2">General stress</td></tr><tr><td><i>uspA</i></td><td>Universal stress global response regulator</td></tr><tr><td><i>rpoS</i></td><td>Regulator of the general stress response (σ<sup>S</sup>)</td></tr><tr><td colspan="2">Starvation</td></tr><tr><td><i>phoA</i></td><td>Alkaline phosphatase</td></tr><tr><td><i>dps</i></td><td>DNA-binding protein from starved cells</td></tr><tr><td colspan="2">Cold shock</td></tr><tr><td><i>cspA</i></td><td>Cold shock protein A</td></tr><tr><td><i>cspC</i></td><td>Cold shock protein C</td></tr><tr><td><i>cspE</i></td><td>Cold shock protein E</td></tr><tr><td colspan="2">UV</td></tr><tr><td><i>mutS</i></td><td>DNA mismatch repair protein—Mutator S</td></tr><tr><td colspan="2">Acid resistance</td></tr><tr><td><i>gadA</i></td><td>Glutamate decarboxylase A</td></tr><tr><td><i>gadB</i></td><td>Glutamate decarboxylase B</td></tr><tr><td><i>gadW</i></td><td>DNA-binding transcriptional activator GadW</td></tr><tr><td colspan="2">Intimin</td></tr><tr><td>eae</td><td>Intimin (adherence protein)</td></tr><tr><td colspan="2">Toxin</td></tr><tr><td><i>stx1A</i></td><td>Shiga-like toxin 1 A subunit</td></tr><tr><td><i>stx2A</i></td><td>Shiga-like toxin 2 A subunit</td></tr><tr><td colspan="2">Motility</td></tr><tr><td><i>fliC</i></td><td>Flagellin</td></tr></table> |
65ea631f68595ffdfce2bb4b38f246dfb5d710764ef9905ab47c54dca319d02b.png | simple | <table><tr><td></td><td>* TPS</td><td>0.5%</td><td>1%</td><td>1.5%</td><td>2%</td></tr><tr><td>T<sub>β</sub></td><td>−46.71</td><td>−40.53</td><td>−36.52</td><td>−38.27</td><td>−39.40</td></tr><tr><td>T<sub>α</sub></td><td>64.38</td><td>64.61</td><td>69.87</td><td>62.65</td><td>64.02</td></tr></table> |
db6bcb448a7a0f0ee867762753cfd5c6a6fea71c6e0f8b6a249a7770d5ec7be9.png | complex | <table><tr><td>Gene</td><td colspan="2">Sequence 5’to 3</td></tr><tr><td>MAPK</td><td>Forward</td><td>CAGTGGGATGGAATTGAAAG</td></tr><tr><td></td><td>Reverse</td><td>AGCAGAAGGAATGAGTGTGC</td></tr><tr><td>NOS1</td><td>Forward</td><td>GACTGTTGAGATGGAAGAAC</td></tr><tr><td></td><td>Reverse</td><td>ATCTTCCTGTCTCCGAGGCG</td></tr><tr><td>NOS3</td><td>Forward</td><td>GTGATGGCGAAGCGAGTGAAG</td></tr><tr><td></td><td>Reverse</td><td>CCGAGCCCGAACACACAGAAC</td></tr><tr><td>PIK3CA</td><td>Forward</td><td>CTCCACGACCATCATCAGG</td></tr><tr><td></td><td>Reverse</td><td>GATTACGAAGGTATTGGTT</td></tr></table> |
c17060b995a4a8ee45a362fa6d9f57a05afebcd691b410b53ab0132f41984ef9.png | complex | <table><tr><td></td><td colspan="2">low fCP</td><td colspan="2">high fCP</td><td colspan="3"><i>P</i> values</td></tr><tr><td></td><td>low fCHO</td><td>high fCHO</td><td>low fCHO</td><td>high fCHO</td><td>fCP</td><td>fCHO</td><td>fCP x fCHO</td></tr><tr><td>Gene expression<sup>1</sup></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><i>DAO</i></td><td>0.97 ± 0.1</td><td>1.05 ± 0.1</td><td>1.19 ± 0.3</td><td>1.02 ± 0.2</td><td>0.55</td><td>0.77</td><td>0.42</td></tr><tr><td><i>HMT</i></td><td>0.88 ± 0.1</td><td>0.84 ± 0.1</td><td>1.05 ± 0.1</td><td>0.96 ± 0.1</td><td>0.033</td><td>0.35</td><td>0.70</td></tr><tr><td><i>C-Kit</i></td><td>0.46 ± 0.1</td><td>0.37 ± 0.1</td><td>0.63 ± 0.1</td><td>0.56 ± 0.1</td><td>0.005</td><td>0.22</td><td>0.82</td></tr><tr><td><i>FcεRI</i></td><td>0.43 ± 0.2</td><td>0.71 ± 0.1</td><td>0.99 ± 0.3</td><td>0.95 ± 0.1</td><td>0.049</td><td>0.30</td><td>0.58</td></tr><tr><td><i>CFTR</i></td><td>0.63 ± 0.06</td><td>0.69 ± 0.07</td><td>0.44 ± 0.03</td><td>0.49 ± 0.03</td><td><0.001</td><td>0.22</td><td>0.96</td></tr><tr><td>Enzyme activity<sup>2</sup></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>DAO </td><td>40.8 ± 5.3</td><td>43.4 ± 5.1</td><td>77.6 ± 14</td><td>64.4 ± 13</td><td>0.001</td><td>0.55</td><td>0.37</td></tr><tr><td>HMT </td><td>290 ± 32</td><td>286 ± 38</td><td>376 ± 56</td><td>394 ± 33</td><td>0.006</td><td>0.84</td><td>0.77</td></tr></table> |
5d8db057bf4db82073a38d77426a87b7efea46fafc77030684168f4ed14fb69a.png | simple | <table><tr><td>Species</td><td>Erroneous sequences</td><td>Corrected sequences</td><td>Apparent rate of correction (%)</td></tr><tr><td><i>H. sapiens</i></td><td>941</td><td>331</td><td>35.2</td></tr><tr><td><i>M. musculus</i></td><td>455</td><td>106</td><td>23.3</td></tr><tr><td><i>R. norvegicus</i></td><td>704</td><td>178</td><td>25.3</td></tr><tr><td><i>M. domestica</i></td><td>434</td><td>93</td><td>21.4</td></tr><tr><td><i>G. gallus</i></td><td>458</td><td>118</td><td>25.8</td></tr><tr><td><i>X. tropicalis</i></td><td>547</td><td>176</td><td>32.2</td></tr><tr><td><i>D. rerio</i></td><td>1376</td><td>180</td><td>13.1</td></tr><tr><td><i>F. rubripes</i></td><td>507</td><td>97</td><td>19.1</td></tr><tr><td><i>B. floridae</i></td><td>1753</td><td>46</td><td>2.6</td></tr><tr><td><i>C. intestinalis</i></td><td>391</td><td>28</td><td>7.2</td></tr><tr><td><i>C. elegans</i></td><td>215</td><td>49</td><td>22.8</td></tr><tr><td><i>D. melanogaster</i></td><td>337</td><td>60</td><td>17.8</td></tr></table> |
947fd6464a5a0657c84a83e7c5fdbd39c7115cba75db43fbdb6088b8dd96f867.png | simple | <table><tr><td>Service</td><td>MD</td><td>NP</td><td>PA</td><td>TOTAL</td></tr><tr><td>N</td><td>N = 125</td><td>N = 23</td><td>N = 21</td><td>169</td></tr><tr><td><i>Multidisciplinary Pain Management</i></td><td></td><td></td><td></td><td></td></tr><tr><td> Any</td><td>106/123 (86%)</td><td>16/23 (70%)</td><td>19/21 (90%)</td><td>141/167(84%)</td></tr><tr><td> 9 or more times</td><td>52/123 (42%)</td><td>7/23 (30%)</td><td>10/21 (48%)</td><td>69/167 (41%)</td></tr><tr><td><i>Comprehensive Nutritional Assessment and Advice</i></td><td></td><td></td><td></td><td></td></tr><tr><td> Any</td><td>99/116 (85%)</td><td>18/22 (88%)</td><td>16/20 (80%)</td><td>133/158 (84%)</td></tr><tr><td> 9 or more times</td><td>43 (37%)</td><td>9/22 (41%)</td><td>8/20 (40%)</td><td>60/158(37%)</td></tr><tr><td><i>Obesity Healthy Lifestyle Promotion</i></td><td></td><td></td><td></td><td></td></tr><tr><td> Any</td><td>99/119 (83%)</td><td>15/23 (65%)</td><td>18/21 (86%)</td><td>132/163 (80%)</td></tr><tr><td> 9 or more times</td><td>53/119 (45%)</td><td>7/23 (30%)</td><td>8/21 (38%)</td><td>68/163 (41%)</td></tr><tr><td><i>Fit for Life (Exercise/Fitness Program)</i></td><td></td><td></td><td></td><td></td></tr><tr><td> Any</td><td>90/116(77%)</td><td>15/23 (65%)</td><td>17/21 (81%)</td><td>122/160(76%)</td></tr><tr><td> 9 or more times</td><td>43 (37%)</td><td>6/23 (26%)</td><td>10/21 (48%)</td><td>59/160(36%)</td></tr><tr><td><i>Diabetes Healthy Lifestyle Promotion</i></td><td></td><td></td><td></td><td></td></tr><tr><td> Any</td><td>86/118 (73%)</td><td>16/23 (70%)</td><td>17/21 (81%)</td><td>119/162 (73%)</td></tr><tr><td> 9 or more times</td><td>38/118 (32%)</td><td>6/23 (26%)</td><td>7/21 (33%)</td><td>51/162 (31%)</td></tr><tr><td><i>Psychology support for biofeedback, hypnosis, Mindfulness-based Stress Reduction, other stress management</i></td><td></td><td></td><td></td><td></td></tr><tr><td> Any</td><td>92/119 (77%)</td><td>13/22 (60%)</td><td>14/21 (67%)</td><td>119/162 (73%)</td></tr><tr><td> 9 or more times</td><td>31 (26%)</td><td>2/22 (9%)</td><td>7/21 (33%)</td><td>40/162 (24%)</td></tr><tr><td><i>Heart Healthy Lifestyle Promotion</i></td><td></td><td></td><td></td><td></td></tr><tr><td> Any</td><td>81/116 (70%)</td><td>16/23(70%)</td><td>18/21 (86%)</td><td>115/160 (71%)</td></tr><tr><td> 9 or more times</td><td>39/116 (34%)</td><td>7/23(30%)</td><td>6/21 (29%)</td><td>52/160 (32%)</td></tr><tr><td><i>Pharmacy Support for questions about herbs and supplements</i></td><td></td><td></td><td></td><td></td></tr><tr><td> Any</td><td>80/119 (67%)</td><td>16/23 (70%)</td><td>16/21 (76%)</td><td>112/163 (68%)</td></tr><tr><td> 9 or more times</td><td>23 (19%)</td><td>6/23 (26%)</td><td>8/21 (38%)</td><td>37/163 (22%)</td></tr><tr><td><i>Comprehensive Back Pain</i></td><td></td><td></td><td></td><td></td></tr><tr><td> Any</td><td>84/123 (68)</td><td>12/23 (52%)</td><td>15/21 (71%)</td><td>111/167 (66%)</td></tr><tr><td> 9 or more times</td><td>32/123 (26%)</td><td>2/23 (9%)</td><td>9/21 (43%)</td><td>43/167 (25%)</td></tr><tr><td><i>Integrative Headache management</i></td><td></td><td></td><td></td><td></td></tr><tr><td> Any</td><td>80/121 (66%)</td><td>12/23 (52%)</td><td>13/21 (62%)</td><td>105/165 (63%)</td></tr><tr><td> 9 or more times</td><td>23/121 (19%)</td><td>1/23(4%)</td><td>6/21 (29%)</td><td>30/165(18%)</td></tr><tr><td><i>Cancer Patient Support Program</i></td><td></td><td></td><td></td><td></td></tr><tr><td> Any</td><td>76/117 (65%)</td><td>10/23 (44%)</td><td>15/21 (71%)</td><td>101/161(62%)</td></tr><tr><td> 9 or more times</td><td>25/117 (21%)</td><td>3/23 (13%)</td><td>5/21 (24%)</td><td>33/161(20%)</td></tr><tr><td><i>Stroke Recovery Program</i></td><td></td><td></td><td></td><td></td></tr><tr><td> Any</td><td>60/120 (50%)</td><td>12/23 (52%)</td><td>12/20 (60%)</td><td>84/163(51%)</td></tr><tr><td> 9 or more times</td><td>10/120 (8%)</td><td>2/23 (9%)</td><td>2/20 (10%)</td><td>14/163(8%)</td></tr></table> |
ef3779f6af29b17177bab25cd4cad40849c5c66e7aa51db75c430ac22f812269.png | simple | <table><tr><td>characteristics</td><td>C/G/BMSCs-dECM scaffolds</td><td>C/G scaffolds</td></tr><tr><td>Pore diameter (μm)</td><td>289.17 ± 80.28</td><td>227.17 ± 44.37</td></tr><tr><td>Porosity (%)</td><td>89.25 ± 3.75</td><td>88.48 ± 2.28</td></tr><tr><td>Water uptake ratio</td><td>13.81 ± 1.00</td><td>11.07 ± 0.87</td></tr><tr><td>Compressive modulus (MPa)</td><td>0.82 ± 0.07</td><td>1.10 ± 0.11</td></tr></table> |
d1854b0e4660f9dad1d224b2b30a27703731da51d186248ea2ebce0564d27a50.png | complex | <table><tr><td rowspan="2"></td><td>Group 1</td><td>Group 2</td><td>Group 3</td><td>Group 4</td><td>ANOVA</td></tr><tr><td><i>n =</i> 15</td><td><i>n =</i> 15</td><td><i>n =</i> 15</td><td><i>n =</i> 15</td><td><i>p</i>-value</td></tr><tr><td>CLD at 36 weeks</td><td>3 (20 %)</td><td>4 (27 %)</td><td>7 (47 %)</td><td>2 (13 %)</td><td>0.2</td></tr><tr><td>Days respiratory support</td><td>21 (9, 33)</td><td>26 (20, 38)</td><td>30 (24, 33)</td><td>24 (10, 35)</td><td>0.4</td></tr><tr><td>Days hospital stay</td><td>50 (39, 58)</td><td>53 (41, 71)</td><td>64 (50, 78)</td><td>53 (48, 66)</td><td>0.2</td></tr><tr><td>Days to full suck feeds</td><td>40 (35, 54)</td><td>51 (36, 66)</td><td>57 (41, 73)</td><td>51 (37, 64)</td><td>0.5</td></tr><tr><td>Days NCPAP</td><td>1 (0, 12)</td><td>24 (9, 28)</td><td>15 (11, 21)</td><td>24 (10, 35)</td><td>0.002</td></tr><tr><td rowspan="2">Gestational age off NCPAP</td><td>31.6</td><td>33.9</td><td>35.7</td><td>34.6</td><td rowspan="2">0.04</td></tr><tr><td>(30.0, 34.1)</td><td>(32.1, 35.9)</td><td>(31.0, 37.6)</td><td>(31.9, 35.3)</td></tr><tr><td>Days HFNC from start of treatment</td><td>15 (7, 24)</td><td></td><td>30 (20, 34)</td><td></td><td>0.004</td></tr><tr><td>Days pressure support</td><td>15 (9, 29)</td><td>24 (9, 28)</td><td>30 (24, 33)</td><td>24 (10, 35)</td><td>0.1</td></tr><tr><td rowspan="2">Gestational age off pressure support</td><td>34.0</td><td>33.9</td><td>35.9</td><td>34.6</td><td rowspan="2">0.07</td></tr><tr><td>(32.7, 35.3)</td><td>(32.1, 35.9)</td><td>(33.9, 38.9)</td><td>(31.9, 35.3)</td></tr><tr><td rowspan="2">Gestational age off respiratory support</td><td>34.7</td><td>34.1</td><td>35.9</td><td>34.6</td><td rowspan="2">0.1</td></tr><tr><td>(33.4, 35.3)</td><td>(33.1, 36.0)</td><td>(33.9, 38.9)</td><td>(31.9, 35.3)</td></tr><tr><td rowspan="2">Gestational age at full suck feeds</td><td>36.9</td><td>37.1</td><td>39.6</td><td>37.3</td><td rowspan="2">0.1</td></tr><tr><td>(36.4, 38.0)</td><td>(36.1, 40.6)</td><td>(37.1, 44.0)</td><td>(36.6, 39.1)</td></tr><tr><td rowspan="2">Gestation at discharge</td><td>37.7</td><td>37.9</td><td>39.9</td><td>38.3</td><td rowspan="2">0.1</td></tr><tr><td>(36.9, 39.1)</td><td>(37.1, 40.1)</td><td>(37.9, 45.0)</td><td>(36.9, 39.7)</td></tr><tr><td>Postnatal growth failure</td><td>9 (60 %)</td><td>9 (60 %)</td><td>7 (47 %)</td><td>7 (47 %)</td><td>0.8</td></tr><tr><td>Weight at 36 weeks - g (sd)</td><td>2158 (411)</td><td>2044 (390)</td><td>2042 (338)</td><td>2128 (532)</td><td>0.4</td></tr><tr><td>Days caffeine</td><td>24 (24)</td><td>34 (30)</td><td>40 (22)</td><td>39 (33)</td><td>0.2</td></tr><tr><td>Grade 2 apnea (required IPPV)</td><td>0</td><td>1 (7 %)</td><td>0</td><td>0</td><td>0.4</td></tr><tr><td>Necrotising enterocolitis</td><td>0</td><td>1 (7 %)</td><td>0</td><td>0</td><td>0.4</td></tr><tr><td>Treated ductus arteriosus</td><td>2 (13 %)</td><td>5 (33 %)</td><td>4 (27 %)</td><td>1 (7 %)</td><td>0.2</td></tr><tr><td>Retinopathy of prematurity</td><td>7 (47 %)</td><td>6 (40 %)</td><td>6 (40 %)</td><td>6 (40 %)</td><td>0.6</td></tr><tr><td>Laser therapy</td><td>1 (7 %)</td><td>0</td><td>0</td><td>1 (7 %)</td><td>0.6</td></tr><tr><td>Nasal injury</td><td>0</td><td>0</td><td>1 (7 %)</td><td>1 (7 %)</td><td>0.4</td></tr><tr><td>Withdrawn</td><td>0</td><td>6 (40 %)</td><td>1 (7 %)</td><td>0</td><td>0.01</td></tr></table> |
17d6a203712dafc3a64b93c58a6714bdd0ed3d7b547174345de6e00b0a445e14.png | complex | <table><tr><td colspan="3">Defense related transcripts Leaf</td><td colspan="3">Stress related transcripts Leaf</td></tr><tr><td>EST/mRNA</td><td>Fold</td><td>Description</td><td>EST/mRNA</td><td>Fold</td><td>Description</td></tr><tr><td>EH615198</td><td>6.4</td><td><i>Nicotiana tabacum </i>nictaba mRNA (NT1)</td><td>TA14956_4097</td><td>3.8</td><td><i>Tamarix </i>Putative stress-responsive protein</td></tr><tr><td>FG636567</td><td>3.8</td><td><i>Nicotiana tabacum </i>mRNA for P-rich protein NtEIG-C29</td><td>FG156808</td><td>3.6</td><td><i>Nicotiana tabacum </i>1-D-deoxyxylulose 5-phosphate synthase mRNA (DXS1)</td></tr><tr><td>EB433973</td><td>2.8</td><td>Parsley PcPR1-3 mRNA for pathogenesis-related protein type B</td><td>CV016057</td><td>2.9</td><td><i>Arabidopsis thaliana </i>cold-regulated 413-plasma membrane 2 mRNA COR413-PM2</td></tr><tr><td>S44869</td><td>2.4</td><td><i>Nicotiana tabacum </i>Endochitinase A precursor</td><td>EB441160</td><td>2.9</td><td><i>Solanum lycopersicum </i>dxs2 gene for 1-deoxy-D-xylulose 5-phosphate synthase</td></tr><tr><td>X12739</td><td>2.1</td><td><i>Nicotiana tabacum </i>Pathogenesis-related protein R major form precursor</td><td>EB435759</td><td>2.8</td><td><i>Ipomoea nil </i>In04 mRNA for caffeoyl-CoA O-methyltransferase</td></tr><tr><td>TA14009_4097</td><td>0.5</td><td><i>Nicotiana tabacum </i>Chitinase 134</td><td>TA12600_4097</td><td>2.8</td><td><i>Solanum tuberosum </i>Low temperature and salt responsive protein</td></tr><tr><td>EB425556</td><td>0.5</td><td><i>Arabidopsis thaliana </i>beta-1,3-glucanase-related mRNA</td><td>EB451519</td><td>2.8</td><td><i>Solanum lycopersicum </i>geranylgeranyl pyrophosphate synthase 1 (GGPS1)</td></tr><tr><td>EH624302</td><td>0.5</td><td><i>Arabidopsis thaliana </i>callose synthase 1 mRNA CALS1</td><td>EB445705</td><td>2.7</td><td><i>Vitis vinifera </i>RD22-like protein mRNA</td></tr><tr><td colspan="3">Defense related transcripts Flower</td><td>DV161729</td><td>2.1</td><td><i>Arabidopsis thaliana </i>snf1-related protein kinase 2.2, SNRK2.2</td></tr><tr><td>FG167555</td><td>3.8</td><td><i>Nicotiana tabacum </i>Avr9/Cf-9 rapidly elicited protein 111B (ACRE111B) AP2-DOMAIN</td><td>FG633784</td><td>2.0</td><td><i>Solanum lycopersicum </i>anthocyanin acyltransferase mRNA, Jasmonic acid inducible</td></tr><tr><td>AB041516</td><td>3.5</td><td><i>Nicotiana tabacum </i>P-rich protein EIG-I30</td><td>EB680165</td><td>0.3</td><td><i>Arabidopsis thaliana </i>SIP3 (SOS3-INTERACTING PROTEIN 3)</td></tr><tr><td>TA14524_4097</td><td>3.0</td><td><i>Nicotiana tabacum </i>Avr9/Cf-9 rapidly elicited protein 65 (ACRE65) mRNA,</td><td>EB433693</td><td>0.4</td><td><i>Arabidopsis thaliana </i>AFP1 (ABI FIVE BINDING PROTEIN)</td></tr><tr><td>FG640154</td><td>2.6</td><td><i>Nicotiana tabacum </i>mRNA for basic pathogenesis-related protein Thaumatin</td><td>TA14058_4097</td><td>0.4</td><td><i>Ipomoea nil </i>CHS-D mRNA for chalcone synthase</td></tr><tr><td>FG635113</td><td>2.5</td><td><i>Nicotiana tabacum </i>Avr9/Cf-9 rapidly elicited protein 20 (ACRE20) mRNA; EF-hand calcium binding protein</td><td>EB439278</td><td>0.4</td><td><i>Nicotiana tabacum </i>NtERD10B mRNA for dehydrin</td></tr><tr><td>TA13004_4097</td><td>2.2</td><td><i>Nicotiana tabacum </i>mRNA for hin1 gene: Harpin inducing protein</td><td>EB437158</td><td>0.5</td><td><i>Ricinus communis </i>leuco-anthocyanidin dioxygenase mRNA</td></tr><tr><td>TA15227_4097</td><td>2.1</td><td><i>Nicotiana tabacum </i>Avr9/Cf-9 rapidly elicited protein 76; NDR1/HIN1</td><td>DW003496</td><td>0.5</td><td><i>Ricinus communis </i>Salt-tolerance protein</td></tr><tr><td>AB127582</td><td>2.1</td><td><i>Nicotiana tabacum </i>Harpin inducing protein 1-like 18 DOMAIN: LEA_2</td><td>EB438355</td><td>0.5</td><td><i>Arabidopsis thaliana </i>ATHK1 (histidine kinase 1/ osmosensor)</td></tr><tr><td></td><td></td><td></td><td>EB438355</td><td>0.5</td><td><i>Catharanthus roseus </i>cold inducible histidine kinase 1 (iK1) mRNA</td></tr></table> |
56edb093741e6f2cc0efe31c3cb711b105c613b59d4224780feb36f7c539d757.png | complex | <table><tr><td><i>n </i>= 136</td><td>Total</td><td colspan="2">Possible or specific OA diagnosis on GP request</td></tr><tr><td></td><td></td><td><i>n </i>(%)</td><td>OR<sup>a </sup>(95% CI)</td></tr><tr><td>Male</td><td>62</td><td>20 (32%)</td><td>1.00</td></tr><tr><td>Female</td><td>74</td><td>30 (41%)</td><td>1.51 (0.73, 3.11)</td></tr><tr><td>Age</td><td></td><td></td><td></td></tr><tr><td> under 60</td><td>69</td><td>19 (28%)</td><td>1.00</td></tr><tr><td> 60 & over</td><td>67</td><td>31 (46%)</td><td>2.32 (1.13, 4.77)</td></tr></table> |
34f0abf17b8e83a42663034f1b56b5431af6415878c99958a676f6960add3f59.png | simple | <table><tr><td>Province</td><td>City</td><td>PCR-confirmed<i>P. falciparum</i>(N)</td></tr><tr><td>Khyber Pakhtunkhwa</td><td>Bannu</td><td>39</td></tr><tr><td> </td><td>Hangu</td><td>19</td></tr><tr><td> </td><td>Peshawar</td><td>4</td></tr><tr><td> </td><td>Thal</td><td>29</td></tr><tr><td>Punjab</td><td>Bhakkar</td><td>1</td></tr><tr><td> </td><td>Lahore</td><td>1</td></tr><tr><td> </td><td>Mianwali</td><td>28</td></tr><tr><td> </td><td>Muzaffarghar</td><td>13</td></tr><tr><td> </td><td>Rawalpindi</td><td>0</td></tr><tr><td>Balochistan</td><td>Quetta</td><td>26</td></tr><tr><td> </td><td>Zhob</td><td>7</td></tr><tr><td>Sindh</td><td>Hyderabad</td><td>0</td></tr><tr><td> </td><td>Karachi</td><td>2</td></tr><tr><td>Capital</td><td>Islamabad</td><td>2</td></tr><tr><td>Total</td><td> </td><td>171</td></tr></table> |
f20a9501fe20aadccc10b16d77dc1522410128a0671f314a2ca9bf15c40fe6e7.png | complex | <table><tr><td rowspan="2">Animal group</td><td rowspan="2">Number ofhemispheres used</td><td colspan="2">MaxPs of activation evoked byF and revF stimulation</td><td colspan="2">Comparison between sound types</td></tr><tr><td>F</td><td>revF</td><td>Type of test</td><td><i>p</i> values</td></tr><tr><td>Trained</td><td>12</td><td>0.212 ± 0.063</td><td>0.116 ± 0.029</td><td><i>t</i> test</td><td>8.74E-05</td></tr><tr><td>Naïve</td><td>12</td><td>0.199 ± 0.060</td><td>0.114 ±0.026</td><td><i>t</i> test</td><td>1.97E-04</td></tr></table> |
937571b88e4fbac992413f3db3550d38ce635ca2b4ced8f36c88514d992b9123.png | complex | <table><tr><td></td><td>Control group(n = 128)</td><td>ConventionalIVF group(n = 114)</td><td>ICSI group(n = 140)</td><td>p-value</td></tr><tr><td>Maternal age (yr)</td><td>34.52 ± 4.13</td><td>35.70 ± 3.97</td><td>35.49 ± 4.23</td><td>0.055</td></tr><tr><td>Paternal age (yr)</td><td>36.05 ± 4.34<sup>a</sup></td><td>37.43 ± 4.39<sup>a,b</sup></td><td>38.07 ± 5.40<sup>b</sup></td><td>0.002</td></tr><tr><td>Maternal BMI</td><td>21.13 ± 2.49</td><td>21.16 ± 3.04</td><td>21.73 ± 2.93</td><td>0.162</td></tr><tr><td colspan="5">Semen analysis</td></tr><tr><td> Volume (ml)</td><td>2.91 ± 1.59</td><td>2.83 ± 1.18</td><td>2.57 ± 1.42</td><td>0.167</td></tr><tr><td> Count (x10<sup>6</sup>/ml)</td><td>91.85 ± 43.72 <sup>a</sup></td><td>93.62 ± 58.41 <sup>a</sup></td><td>66.48 ± 66.50 <sup>b</sup></td><td>< 0.001</td></tr><tr><td> Morphology, strict</td><td>6.14 ± 2.36 <sup>a</sup></td><td>6.68 ± 2.86 <sup>a</sup></td><td>4.25 ± 3.57 <sup>b</sup></td><td>< 0.001</td></tr><tr><td> Motility</td><td>47.90 ± 15.46 <sup>a</sup></td><td>48.56 ± 16.75 <sup>a</sup></td><td>37.99 ± 21.11 <sup>b</sup></td><td>< 0.001</td></tr><tr><td colspan="5">Hormonal profile</td></tr><tr><td> Basal FSH (u/ml)</td><td>7.17 ± 2.76</td><td>7.49 ± 5.08</td><td>7.28 ± 3.58</td><td>0.886</td></tr><tr><td> Basal LH (u/ml)</td><td>4.18 ± 4.01</td><td>3.06 ± 1.71</td><td>3.83 ± 3.08</td><td>0.127</td></tr><tr><td> Basal E2 (pg/ml)</td><td>28.25 ± 14.29</td><td>28.41 ± 21.74</td><td>30.44 ± 24.19</td><td>0.729</td></tr><tr><td>Fetal gestational age at D&E (days)</td><td>59.66 ± 8.23</td><td>61.00 ± 7.51</td><td>60.98 ± 7.77</td><td>0.300</td></tr><tr><td colspan="5">Previous pregnancy status (n)</td></tr><tr><td> Parity</td><td>1.63 ± 1.47<sup>a</sup></td><td>1.32 ± 1.51<sup>a,b</sup></td><td>0.99 ± 1.18<sup>b</sup></td><td>0.001</td></tr><tr><td> Abortion</td><td>1.11 ± 1.21<sup>a</sup></td><td>0.61 ± 0.98<sup>b</sup></td><td>0.49 ± 0.66<sup>b</sup></td><td>< 0.001</td></tr></table> |
74efcf3db64f530e6375c996a148ca58bb3a29ad6534f5f27fb244ec70613667.png | complex | <table><tr><td>Rank</td><td colspan="3">Tissues</td><td colspan="3">Different developing flowers</td><td colspan="3">Total</td></tr><tr><td></td><td>Gene name</td><td>Coefficient of correlation (r)</td><td><i>p</i>-value</td><td>Gene name</td><td>Coefficient of correlation (r)</td><td><i>p</i>-value</td><td>Gene name</td><td>Coefficient of correlation (r)</td><td><i>p</i>-value</td></tr><tr><td>1</td><td><i>EF1-</i>α</td><td>0.91</td><td>0.004</td><td><i>FAD</i></td><td>0.99</td><td>0.001</td><td><i>EF1-</i>α</td><td>0.94</td><td>0.001</td></tr><tr><td>2</td><td><i>RPL3</i></td><td>0.90</td><td>0.005</td><td><i>EF1-</i>α</td><td>0.99</td><td>0.001</td><td><i>FAD</i></td><td>0.92</td><td>0.001</td></tr><tr><td>3</td><td><i>18S</i></td><td>0.84</td><td>0.017</td><td><i>EF1-</i>γ</td><td>0.95</td><td>0.003</td><td><i>RPL3</i></td><td>0.91</td><td>0.001</td></tr><tr><td>4</td><td><i>ACT5</i></td><td>0.80</td><td>0.031</td><td><i>ACT5</i></td><td>0.95</td><td>0.004</td><td><i>EF1-</i>γ</td><td>0.85</td><td>0.001</td></tr><tr><td>5</td><td><i>FAD</i></td><td>0.79</td><td>0.034</td><td><i>NAC</i></td><td>0.94</td><td>0.006</td><td><i>18S</i></td><td>0.81</td><td>0.001</td></tr><tr><td>6</td><td><i>NAC</i></td><td>0.62</td><td>0.139</td><td><i>ACT7</i></td><td>0.93</td><td>0.007</td><td><i>ACT7</i></td><td>0.79</td><td>0.001</td></tr><tr><td>7</td><td><i>EF1-</i>γ</td><td>0.62</td><td>0.141</td><td><i>RPL3</i></td><td>0.92</td><td>0.010</td><td><i>NAC</i></td><td>0.76</td><td>0.003</td></tr><tr><td>8</td><td><i>GAPDH</i></td><td>0.59</td><td>0.168</td><td><i>GAPDH</i></td><td>0.88</td><td>0.021</td><td><i>ACT5</i></td><td>0.73</td><td>0.005</td></tr><tr><td>9</td><td><i>UBC</i></td><td>0.51</td><td>0.241</td><td><i>18S</i></td><td>0.83</td><td>0.040</td><td><i>GAPDH</i></td><td>0.66</td><td>0.013</td></tr><tr><td>10</td><td><i>ACT7</i></td><td>0.42</td><td>0.350</td><td><i>UBC</i></td><td>0.33</td><td>0.523</td><td><i>UBC</i></td><td>0.35</td><td>0.241</td></tr></table> |
bf9c1fcd5b72d9635907f9b507b30033560d74eeb5aec795d7b8eba910d1b8d6.png | complex | <table><tr><td>Location</td><td><i>X</i></td><td><i>Y</i></td><td><i>Z</i></td><td>Extent</td><td>Z-value</td></tr><tr><td colspan="6">Univariate effect of degradation [((NV + SW)/2) > CL]</td></tr><tr><td>Left inferior frontal gyrus (p. Opercularis)</td><td>−54</td><td>10</td><td>20</td><td>555</td><td>3.92</td></tr><tr><td> Left precentral gyrus</td><td>−52</td><td>8</td><td>30</td><td></td><td>3.86</td></tr><tr><td> Left precentral gyrus</td><td>−46</td><td>2</td><td>28</td><td></td><td>3.80</td></tr><tr><td colspan="6">Multivariate acoustic form coding</td></tr><tr><td>Left posterior STG</td><td>−63</td><td>−33</td><td>15</td><td>392</td><td>4.94</td></tr><tr><td> Left mid-STG</td><td>−57</td><td>−12</td><td>4</td><td></td><td>4.62</td></tr><tr><td> Left mid-anterior STG</td><td>−54</td><td>−6</td><td>−4</td><td></td><td>4.37</td></tr><tr><td>Right posterior STG</td><td>54</td><td>−42</td><td>15</td><td>254</td><td>4.13</td></tr><tr><td> Right anterior STG</td><td>57</td><td>12</td><td>−8</td><td></td><td>3.99</td></tr><tr><td> Right supramarginal Gyrus</td><td>54</td><td>−36</td><td>26</td><td></td><td>3.83</td></tr><tr><td colspan="6">Multivariate syllable identity coding</td></tr><tr><td>Left mid-posterior left STG</td><td>−63</td><td>−24</td><td>8</td><td>303</td><td>4.59</td></tr><tr><td> Left mid-STG</td><td>−48</td><td>−15</td><td>0</td><td></td><td>4.38</td></tr><tr><td> Left posterior STS</td><td>−57</td><td>−39</td><td>8</td><td></td><td>4.21</td></tr><tr><td>Right posterior STG</td><td>69</td><td>−30</td><td>11</td><td>172</td><td>4.44</td></tr><tr><td> Right posterior STG</td><td>57</td><td>−27</td><td>8</td><td></td><td>4.19</td></tr><tr><td> Right mid-STG</td><td>63</td><td>−18</td><td>0</td><td></td><td>3.99</td></tr><tr><td>Left precentral gyrus</td><td>−51</td><td>0</td><td>41</td><td>83</td><td>4.39</td></tr><tr><td> Left postcentral gyrus</td><td>−60</td><td>−3</td><td>38</td><td></td><td>3.97</td></tr></table> |
7f332c509b34aab7e5318da2d4fc6896a20b0ab3209a89304ad873d646601225.png | complex | <table><tr><td rowspan="2">Lineage</td><td colspan="8">ρ (no. of crossovers/Mbp/generation) on chromosome<sup>a</sup></td><td rowspan="2">% homoplastic SNPs</td><td rowspan="2">phi test <i>P</i> value</td></tr><tr><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td>6</td><td>7</td><td>Mean</td></tr><tr><td>1</td><td>8.6*</td><td>3.8*</td><td>15.1*</td><td>1.4</td><td>8.5*</td><td>10.6*</td><td>13.5*</td><td>10.57</td><td>34.56</td><td>0.0000</td></tr><tr><td>2</td><td>0.0</td><td>0.2</td><td>0.2*</td><td>0.3</td><td>0.6</td><td>0.5</td><td>0.3</td><td>0.28</td><td>0.09</td><td>0.0944</td></tr><tr><td>3</td><td>0.4*</td><td>0.2*</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.01</td><td>0.47</td><td>0.0535</td></tr><tr><td>4</td><td>0.2</td><td>0.2*</td><td>0.3</td><td>0.4</td><td>0.4</td><td>0.4</td><td>0.4</td><td>0.33</td><td>0.40</td><td>0.0014</td></tr></table> |
6ae95adadc930b9d3af89925f5a474041d429329bbb00d7d28a570fa879d8d99.png | complex | <table><tr><td>Author</td><td>Age and sex</td><td>Mechanism</td><td>Fielding type</td><td>Associated injuries</td><td>Duration to diagnosis</td><td>Reduction method and treatment</td><td>Results</td></tr><tr><td>Castel et al., 2001 [4]</td><td>41 M</td><td>Rugby injury</td><td>I</td><td>(—)</td><td>1 month</td><td>Reduction and Minerva jacket</td><td>Good</td></tr><tr><td>Fuentes et al., 2001 [5]</td><td>24 M</td><td>Suicidal jump</td><td>IV</td><td>Initial odontoid fracture only</td><td>1 month</td><td>C1-C2 fusion</td><td>Unknown</td></tr><tr><td>Kim et al., 2007 [8]</td><td>34 M</td><td>Fall down from high place</td><td>II</td><td>Lt superior facet fracture of C2</td><td>1 day</td><td>C1-C2 fusion</td><td>Good</td></tr><tr><td rowspan="3">Sinigaglia et al., 2008 [11]</td><td>26 F</td><td>Road traffic accident</td><td>I</td><td>(—)</td><td>45 days</td><td>Reduction and halo vest</td><td>Fair; because of cervical stiffness and headache</td></tr><tr><td>21 F</td><td>Road traffic accident</td><td>I</td><td>(—)</td><td>1 day</td><td>Reduction and halo vest</td><td>Good</td></tr><tr><td>29 M</td><td>Road traffic accident</td><td>I</td><td>(—)</td><td>1 day</td><td>Reduction and rigid collar</td><td>Good</td></tr><tr><td>Wang et al., 2008 [14]</td><td>44 F</td><td>Not described</td><td>I</td><td>(—)</td><td>6 months</td><td>Immobilization with halo vest</td><td>Poor; because of bilateral hand numbness</td></tr><tr><td>Goel et al., 2010 [6]</td><td>28 M</td><td>Fall down from high place</td><td>Not described</td><td>Odontoid fracture</td><td>1 day</td><td>Intraoperative facet manipulation</td><td>Good</td></tr><tr><td>Singh et al., 2009 [10]</td><td>25 F</td><td>Road traffic accident</td><td>I</td><td>(—)</td><td>0 day</td><td>Skull traction and halo brace</td><td>Good</td></tr><tr><td>Jeon et al., 2009 [7]</td><td>25 F</td><td>Road traffic accident</td><td>I</td><td>Thoracic fractures, alar ligament injury</td><td>5 days</td><td>Immobilization with Philadelphia brace</td><td>Good</td></tr><tr><td>Stenson, 2011 [12]</td><td>31 F</td><td>Falling backward</td><td>I</td><td>(—)</td><td>0 day</td><td>Immobilization with hard collar</td><td>Good</td></tr><tr><td>Marti et al., 2011 [9]</td><td>24 F</td><td>Stretching neck herself</td><td>I</td><td>(—)</td><td>1 day</td><td>Reduction and halo vest</td><td>Good</td></tr><tr><td rowspan="2">Venkatesan et al., 2012 [13]</td><td>20 F</td><td>Road traffic accident</td><td>I</td><td>(—)</td><td>0 day</td><td>Skull traction and hard collar</td><td>Fair; because of occipital pain</td></tr><tr><td>52 F</td><td>Road traffic accident</td><td>I</td><td>(—)</td><td>0 day</td><td>Halo traction and hard collar</td><td>Fair; because of occipital pain</td></tr></table> |
deeee0404385bfd92e9146a524fd5ca5fe6ebb2ec11fee70940005b7fcf5c59f.png | complex | <table><tr><td>DDI, min.</td><td colspan="2">Blood Loss (mls)</td><td></td><td></td><td colspan="3">Hospital Stay (days)</td><td></td></tr><tr><td></td><td><1000</td><td>>1000</td><td>COR(95% CI)</td><td>AOR(95% CI)</td><td>≤4</td><td>>4</td><td>COR(95% CI)</td><td>AOR(95% CI)</td></tr><tr><td colspan="9">DDI</td></tr><tr><td>< 30</td><td>72(98.6)</td><td>1(1.4)</td><td>1</td><td>1</td><td>59(12.6)</td><td>14(10.9)</td><td>1</td><td></td></tr><tr><td> 30–75</td><td>288(99.7)</td><td>1(0.3)</td><td>0.25[0.02–4.05]</td><td>0.55[0.03–10.3]</td><td>231(49.3)</td><td>58(44.9)</td><td>1.06[0.55–2.03]</td><td>0.76[0.36–1.61]</td></tr><tr><td>> 75</td><td>235(99.6)</td><td>1(0.4)</td><td>0.31[0.0–4.96]</td><td>3.21[0.02–653.9]</td><td>179(38.1)</td><td>57(44.2)</td><td>1.34[0.7–2.58]</td><td>0.78[0.32–1.81]</td></tr><tr><td colspan="9">30 min</td></tr><tr><td>≤ 30</td><td>72(98.6)</td><td>1(1.4)</td><td>1</td><td>1</td><td>59(12.6)</td><td>14(10.9)</td><td>1</td><td>1</td></tr><tr><td>> 30</td><td>523(99.6)</td><td>2(0.4)</td><td>0.28[0.02–3.07]</td><td>0.55[0.03–10.3]</td><td>410(87.4)</td><td>115(89.1)</td><td>1.18[0.64–2.19]</td><td>0.76[0.36–1.62]</td></tr><tr><td colspan="9">75 min</td></tr><tr><td>≤ 75</td><td>360(99.4)</td><td>2(0.6)</td><td>1</td><td>1</td><td>290(61.8)</td><td>72(55.8)</td><td>1</td><td>1</td></tr><tr><td>> 75</td><td>235(99.6)</td><td>1(0.4)</td><td>0.77[0.07–8.49]</td><td>5.79[0.05–7.18]</td><td>179(38.2)</td><td>57(44.2)</td><td>1.28[0.86–1.9]</td><td>1.02[0.63–1.64]</td></tr></table> |
d589ae2b7a52030decab1b5701fdeafb424f14f91d8fe8994f26969c08541a65.png | simple | <table><tr><td>Filter type</td><td>Central Frequency,<i>f</i><sub>0</sub></td><td>Rotation Variation Parameter,<i>c</i></td><td>Half Central Bandwidth, bw</td><td>Number of Comb Teeth,<i>n</i></td></tr><tr><td>Comblet filter: BSF</td><td>127.178 Hz</td><td>2%</td><td>1.272 Hz</td><td>100</td></tr><tr><td>Comblet filter: BPFI</td><td>308.242 Hz</td><td>2%</td><td>3.082 Hz</td><td>41</td></tr><tr><td>Comblet filter: BPFO</td><td>171.758 Hz</td><td>2%</td><td>1.718 Hz</td><td>74</td></tr><tr><td>Comblet filter: FTF</td><td>28.626 Hz</td><td>2%</td><td>0.286 Hz</td><td>447</td></tr></table> |
cf18d1170dc3f4980c7762fb86994eda4da57f6851078c0fce2051cf4d0f9a88.png | complex | <table><tr><td>SNP</td><td>Group</td><td>WT/HT/MT</td><td colspan="3">Genotypes OR (95%CI)*</td><td><i>P</i>-HWE</td></tr><tr><td></td><td></td><td></td><td>Additive</td><td>Dominant</td><td>Recessive</td><td></td></tr><tr><td>rs1065780</td><td>Control</td><td>661/1091/455</td><td>0.974(0.89-1.065)</td><td>0.984(0.857-1.129)</td><td>0.942(0.806-1.102)</td><td>0.901</td></tr><tr><td>(A>G)</td><td>Case</td><td>607/1001/404</td><td><i>P</i>=0.562</td><td><i>P</i>=0.814</td><td><i>P</i>=0.457</td><td></td></tr><tr><td>rs2854843</td><td>Control</td><td>964/991/254</td><td>1.058(0.963-1.163)</td><td>1.105(0.972-1.255)</td><td>1.007(0.827-1.226)</td><td>0.977</td></tr><tr><td>(T>C)</td><td>Case</td><td>829/949/234</td><td><i>P</i>=0.243</td><td><i>P</i>=0.126</td><td><i>P</i>=0.942</td><td></td></tr><tr><td>rs1874479</td><td>Control</td><td>1461/666/80</td><td>1.057(0.944-1.184)</td><td>1.063(0.931-1.214)</td><td>1.094(0.782-1.53)</td><td>0.704</td></tr><tr><td>(A>G)</td><td>Case</td><td>1290/646/76</td><td><i>P</i>=0.339</td><td><i>P</i>=0.363</td><td><i>P</i>=0.599</td><td></td></tr><tr><td>rs3110697</td><td>Control</td><td>1299/771/133</td><td>1.099(0.99-1.22)</td><td>1.176(1.035-1.336)</td><td>0.908(0.691-1.192)</td><td>0.194</td></tr><tr><td>(G>A)</td><td>Case</td><td>1115/785/110</td><td><i>P</i>=0.076</td><td><i>P</i>=0.013</td><td><i>P</i>=0.486</td><td></td></tr><tr><td>rs13223993</td><td>Control</td><td>939/1007/259</td><td>1.052(0.957-1.156)</td><td>1.093(0.962-1.243)</td><td>1.011(0.832-1.228)</td><td>0.66</td></tr><tr><td>(G>A)</td><td>Case</td><td>810/960/240</td><td><i>P</i>=0.291</td><td><i>P</i>=0.173</td><td><i>P</i>=0.915</td><td></td></tr><tr><td>rs2132572</td><td>Control</td><td>1505/622/77</td><td>1.167(1.041-1.309)</td><td>1.235(1.081-1.411)</td><td>0.992(0.703-1.399)</td><td>0.202</td></tr><tr><td>(C>T)</td><td>Case</td><td>1283/654/72</td><td><i>P</i>=0.008</td><td><i>P</i>=0.002</td><td><i>P</i>=0.962</td><td></td></tr><tr><td>rs2453839</td><td>Control</td><td>1363/738/105</td><td>1.105(0.993-1.23)</td><td>1.117(0.982-1.271)</td><td>1.192(0.895-1.587)</td><td>0.691</td></tr><tr><td>(T>C)</td><td>Case</td><td>1196/703/112</td><td><i>P</i>=0.066</td><td><i>P</i>=0.093</td><td><i>P</i>=0.23</td><td></td></tr></table> |
1c14a07159d569f804bbc05ca1be4cf084c962122b27e5469c9afe23670c575c.png | simple | <table><tr><td>Program participation rate (%)</td><td>Projected number of participants</td><td>Total DME program costs</td><td>Total medical care cost savings</td><td>Medical cost savings net of program cost in 26 counties</td></tr><tr><td>5</td><td>9,365</td><td>$6,087,250</td><td>$18,486,510</td><td>$12,399,459</td></tr><tr><td>10</td><td>18,730</td><td>$12,174,500</td><td>$36,973,020</td><td>$24,798,917</td></tr><tr><td>15</td><td>28,095</td><td>$18,261,750</td><td>$55,459,530</td><td>$37,198,376</td></tr><tr><td>20</td><td>37,461</td><td>$24,349,650</td><td>$73,948,014</td><td>$49,597,834</td></tr><tr><td>50</td><td>93,652</td><td>$60,873,800</td><td>$184,869,048</td><td>$123,994,586</td></tr><tr><td>75</td><td>140,477</td><td>$91,310,050</td><td>$277,301,598</td><td>$185,991,879</td></tr></table> |
138c542f18d73c3e3115786c8fd99ed65550ba8cd8d37d7b7fa20093bf44ece5.png | simple | <table><tr><td><i>S/N</i></td><td><i>Demographic characteristics</i></td><td><i>No of cases</i></td><td><i>Percentage</i></td><td><i>Chi square test</i></td><td><i>P Value</i></td></tr><tr><td>1</td><td><i>Age:</i>a. up to 20 yearsb. 21-40 yearsc. 41 years and above</td><td>3417</td><td>5.8880.3913.75</td><td>79.411737.686253.6862</td><td></td></tr><tr><td>2</td><td><i>Parity:</i>a. Para 0-1b. 2-4c. 5 and above</td><td>61629</td><td>11.7631.3756.86</td><td>59.647014.15681.9215</td><td>0.050.5</td></tr><tr><td>3</td><td><i>Booking Status:</i>a. Bookedb. unbooked</td><td>1338</td><td>25.4974.50</td><td>24.5101</td><td>0.001</td></tr><tr><td>4</td><td><i>Referral status:</i>a. Referred from other placesb. within hospital</td><td>3912</td><td>76.4723.52</td><td>28.5882</td><td>0.001</td></tr><tr><td>5</td><td><i>Level of medical person dealing:</i>a. Paramedics LHV/Nursesb. medical officerc. resident doctord. senior resident</td><td>211893</td><td>41.1735.2917.645.88</td><td>3.17648.823542.705879.4111</td><td> 0.5 0.5 </td></tr></table> |
1abd415f3b7cadf322fef8987c6a6e046dba63308aadb65d67a169b93287a313.png | complex | <table><tr><td rowspan="3">Feature</td><td rowspan="3"></td><td colspan="3">CD163p</td><td colspan="3">CD163i</td></tr><tr><td colspan="2">Freq N (%)</td><td rowspan="2"><i>P</i>-value</td><td colspan="2">Freq N (%)</td><td rowspan="2"><i>P</i>-value</td></tr><tr><td>Low</td><td>High</td><td>Low</td><td>High</td></tr><tr><td>Gender</td><td>Female</td><td>28 (47.5)</td><td>23 (46.0)</td><td>1.0</td><td>24 (44.4)</td><td>25 (48.1)</td><td>0.7121</td></tr><tr><td></td><td>Male</td><td>31 (52.5)</td><td>27 (54.0)</td><td></td><td>30 (55.6)</td><td>27 (51.9)</td><td></td></tr><tr><td>Grade</td><td>G1-2</td><td>6 (10.0)</td><td>6 (12.2)</td><td>0.7179</td><td>4 (7.3)</td><td>8 (15.1)</td><td>0.4874</td></tr><tr><td></td><td>G3</td><td>54 (90.0)</td><td>33 (87.8)</td><td></td><td>51 (92.7)</td><td>45 (84.9)</td><td></td></tr><tr><td>pT</td><td>pT1-2</td><td>8 (13.3)</td><td>7 (14.0)</td><td>1.0</td><td>1 (1.8)</td><td>12 (23.1)</td><td>0.0069</td></tr><tr><td></td><td>pT3</td><td>52 (86.7)</td><td>43 (86.0)</td><td></td><td>54 (98.2)</td><td>40 (76.9)</td><td></td></tr><tr><td>pN</td><td>pN0</td><td>13 (21.7)</td><td>5 (10.0)</td><td>0.2041</td><td>10 (18.2)</td><td>9 (17.0)</td><td>0.8366</td></tr><tr><td></td><td>pN1</td><td>47 (78.3)</td><td>25 (90.0)</td><td></td><td>45 (81.8)</td><td>44 (83.3)</td><td></td></tr><tr><td>pM</td><td>pM0</td><td>36 (61.1)</td><td>29 (58.0)</td><td>1.0</td><td>30 (54.5)</td><td>29 (54.7)</td><td>0.7179</td></tr><tr><td></td><td>pM1</td><td>23 (38.9)</td><td>21 (42.0)</td><td></td><td>25 (45.5)</td><td>24 (45.3)</td><td></td></tr><tr><td>L</td><td>L0</td><td>12 (19.7)</td><td>3 (6.1)</td><td>0.1942</td><td>7 (12.7)</td><td>9 (16.9)</td><td>0.6607</td></tr><tr><td></td><td>L1</td><td>49 (80.3)</td><td>46 (93.9)</td><td></td><td>48 (87.3)</td><td>44 (83.1)</td><td></td></tr><tr><td>V</td><td>V0</td><td>47 (78.3)</td><td>48 (96.0)</td><td>0.0291</td><td>49 (89.1)</td><td>43 (81.1)</td><td>0.3567</td></tr><tr><td></td><td>V1</td><td>13 (21.7)</td><td>2 (4.0)</td><td></td><td>6 (10.9)</td><td>10 (19.9)</td><td></td></tr><tr><td>R</td><td>R0</td><td>43 (71.6)</td><td>37 (75.5)</td><td>0.7955</td><td>39 (70.9)</td><td>41 (77.3)</td><td>0.5523</td></tr><tr><td></td><td>R1</td><td>17 (28.4)</td><td>12 (24.5)</td><td></td><td>16 (29.1)</td><td>12 (22.7)</td><td></td></tr><tr><td>Chemotherapy</td><td>None</td><td>1 (1.7)</td><td>0 (0.0)</td><td>1.0</td><td>0 (0.0)</td><td>1 (1.9)</td><td>1.0</td></tr><tr><td></td><td>Yes</td><td>59 (98.3)</td><td>50 (100.0)</td><td></td><td>55 (100.0)</td><td>52 (98.1)</td><td></td></tr><tr><td>Radiotherapy</td><td>None</td><td>32 (86.5)</td><td>15 (83.3)</td><td>1.0</td><td>23 (92.0)</td><td>24 (80.0)</td><td>0.2689</td></tr><tr><td></td><td>Yes</td><td>5 (13.5)</td><td>3 (16.7)</td><td></td><td>2 (8.0)</td><td>6 (20.0)</td><td></td></tr><tr><td>Budding 10-in-10</td><td>Low</td><td>13 (21.6)</td><td>24 (48.0)</td><td>0.0155</td><td>17 (30.9)</td><td>17 (32.1)</td><td>1.0</td></tr><tr><td></td><td>High</td><td>47 (78.4)</td><td>26 (52.0)</td><td></td><td>38 (69.1)</td><td>36 (67.9)</td><td></td></tr><tr><td>ITB (per punch)</td><td>Low</td><td>19 (31.6)</td><td>27 (57.1)</td><td>0.0253</td><td>19 (34.5)</td><td>25 (47.1)</td><td>0.365</td></tr><tr><td></td><td>High</td><td>41 (68.4)</td><td>22 (42.9)</td><td></td><td>36 (65.5)</td><td>28 (52.9)</td><td></td></tr><tr><td>PTB (per punch)</td><td>Low</td><td>24 (40.0)</td><td>27 (56.0)</td><td>0.0200</td><td>32 (58.1)</td><td>18 (33.9)</td><td>0.0349</td></tr><tr><td></td><td>High</td><td>36 (60.0)</td><td>23 (44.0)</td><td></td><td>23 (41.9)</td><td>35 (66.1)</td><td></td></tr><tr><td>OS</td><td>Median (95%CI)</td><td>10 (9–12)</td><td>13 (10–15)</td><td>0.0823</td><td>12 (9–15)</td><td>11 (9–13)</td><td>0.562</td></tr><tr><td>DFI</td><td>Median (95%CI)</td><td>5 (4–6)</td><td>6 (4–8)</td><td>0.3054</td><td>5 (4–6)</td><td>6 (4–6)</td><td>0.7789</td></tr></table> |
3f006c28f37d7d69e07d516e2dbbfd066084219c9d05b524fc1f56189292ad7e.png | complex | <table><tr><td></td><td colspan="4">Adjusted odds ratio (95% CI) of new-onset depression</td></tr><tr><td></td><td colspan="2">Women (<i>N </i>= 10,178)</td><td colspan="2">Men (<i>N </i>= 30,041)</td></tr><tr><td></td><td>Complete case analysis</td><td>Weighted for non- response</td><td>Complete case analysis</td><td>Weighted for non- response</td></tr><tr><td>Deployment experience</td><td></td><td></td><td></td><td></td></tr><tr><td> Nondeployed</td><td>1.00</td><td>1.00</td><td>1.00</td><td>1.00</td></tr><tr><td> Deployed without combat exposures</td><td>0.65 (0.47, 0.89)</td><td>0.61 (0.44, 0.84)</td><td>0.66 (0.53, 0.83)</td><td>0.65 (0.52, 0.83)</td></tr><tr><td> Deployed with combat exposures</td><td>2.13 (1.70, 2.65)</td><td>1.99 (1.58, 2.50)</td><td>1.32 (1.13, 1.54)</td><td>1.31 (1.12, 1.55)</td></tr><tr><td>Smoking status</td><td></td><td></td><td></td><td></td></tr><tr><td> Never smoker</td><td>1.00</td><td>1.00</td><td>1.00</td><td>1.00</td></tr><tr><td> Past smoker</td><td>1.30 (1.09, 1.55)</td><td>1.34 (1.11, 1.62)</td><td>1.18 (1.02, 1.36)</td><td>1.23 (1.06, 1.43)</td></tr><tr><td> Current smoker</td><td>1.35 (1.10, 1.66)</td><td>1.42 (1.14, 1.78)</td><td>1.52 (1.31, 1.77)</td><td>1.57 (1.33, 1.85)</td></tr><tr><td>Problem drinking</td><td></td><td></td><td></td><td></td></tr><tr><td> No</td><td>1.00</td><td>1.00</td><td>1.00</td><td>1.00</td></tr><tr><td> Yes</td><td>1.27 (1.03, 1.57)</td><td>1.31 (1.04, 1.63)</td><td>1.19 (1.04, 1.37)</td><td>1.23 (1.06, 1.43)</td></tr><tr><td>Posttraumatic stress at baseline</td><td></td><td></td><td></td><td></td></tr><tr><td> No</td><td>1.00</td><td>1.00</td><td>1.00</td><td>1.00</td></tr><tr><td> Yes</td><td>2.98 (2.07, 4.28)</td><td>3.04 (2.09, 4.43)</td><td>4.29 (3.34, 5.50)</td><td>3.91 (2.98, 5.13)</td></tr></table> |
869c44b8a0b894f06ee22e2f496d8b9fa906cbaee1fa066c15e028a6c532d924.png | simple | <table><tr><td>Active sites of catalytic triad</td><td>HRV-C2</td><td>HRV2</td><td>EV71</td><td>PV</td><td>CVB4</td><td>CVB3</td><td>CVA16</td></tr><tr><td>Cys</td><td>105</td><td>106</td><td>110</td><td>109</td><td>110</td><td>110</td><td>110</td></tr><tr><td>His</td><td>34</td><td>18</td><td>21</td><td>20</td><td>21</td><td>18</td><td>21</td></tr><tr><td>Asp</td><td>18</td><td>35</td><td>39</td><td>38</td><td>39</td><td>35</td><td>39</td></tr></table> |
aa78053997d21f1d0ad9863c42f45b10cba447d71ed9ed21560663f962fb6ed2.png | complex | <table><tr><td>Accession numbers</td><td>Gene symbols</td><td colspan="3">Fold change</td></tr><tr><td></td><td></td><td>LEC</td><td>Limbus</td><td>Cornea</td></tr><tr><td colspan="5">WNT signalling pathway</td></tr><tr><td>NM_016269</td><td>LEF1</td><td>(1.2)</td><td>-</td><td>-</td></tr><tr><td>NM_006261</td><td>CDH1</td><td>(5.3)</td><td>-</td><td>(-5.8)</td></tr><tr><td>NM_013263</td><td>BRD7</td><td>(-4.0)</td><td>(1.8)</td><td>(4.0)</td></tr><tr><td>NM_001892</td><td>CSNK1A1</td><td>-</td><td>(4.6)</td><td>-</td></tr><tr><td>AF267864</td><td>TBL1XR1</td><td>-</td><td>-</td><td>(1.9)</td></tr><tr><td>NM_003507</td><td>FZD7</td><td>-</td><td>-</td><td>(2.0)</td></tr><tr><td>NM_022825</td><td>PORCN</td><td>-</td><td>-</td><td>(2.0)</td></tr><tr><td>NM_018890</td><td>RAC1</td><td>(-3.0)</td><td>-</td><td>(3.0)</td></tr><tr><td>NM_001320</td><td>CSNK2B</td><td>(-2.6)</td><td>-</td><td>(2.6)</td></tr><tr><td>NM_014248</td><td>RBX1</td><td>(5.6)</td><td></td><td>(-5.6)</td></tr><tr><td colspan="5">Notch Signalling pathway</td></tr><tr><td>NM_014276</td><td>RBPJL</td><td>(-3.9)</td><td>-</td><td>(3.9)</td></tr><tr><td>NM_005524</td><td>HES1</td><td>(-1.5)</td><td>-</td><td>(2.1)</td></tr><tr><td>NM_203283</td><td>RBPJ</td><td>-</td><td>-</td><td>(4.6)</td></tr><tr><td>NM_033632</td><td>FBXW7</td><td>(-6.1)</td><td>-</td><td>(6.1)</td></tr><tr><td colspan="5">JAK/STAT Signalling pathway</td></tr><tr><td>NM_004232</td><td>SOCS6</td><td>-</td><td>-</td><td>(3.9)</td></tr><tr><td>U52912</td><td>LEPR</td><td>(-3.4)</td><td>(-2.2)</td><td>(3.4)</td></tr><tr><td>U52914</td><td>LEPR</td><td>-</td><td>-</td><td>(2.3)</td></tr><tr><td>AJ271736</td><td>IL9R</td><td>-</td><td>(-4.2)</td><td>(4.2)</td></tr><tr><td>NM_000565</td><td>IL6R</td><td>-</td><td>(-8.7)</td><td>(8.7)</td></tr><tr><td>NM_003150</td><td>STAT3</td><td>-</td><td>-</td><td>(1.7)</td></tr><tr><td>NM_000297</td><td>PKD2</td><td>(-2.8)</td><td>-</td><td>(2.8)</td></tr><tr><td>NM_014432</td><td>IL20RA</td><td>(-4.2)</td><td>-</td><td>(4.2)</td></tr><tr><td colspan="5">TGF-Beta Signalling pathways</td></tr><tr><td>NM_002165</td><td>ID1</td><td>(-3.6)</td><td>(1.5)</td><td>(3.6)</td></tr><tr><td>NM_006350</td><td>FST</td><td>-</td><td>-</td><td>(2.4)</td></tr><tr><td>NM_014248</td><td>RBX1</td><td>(5.6)</td><td>-</td><td>(-5.6)</td></tr><tr><td>NM_002165</td><td>ID1</td><td>(-3.6)</td><td>(1.5)</td><td>(3.6)</td></tr><tr><td colspan="5">BMP Signalling pathway</td></tr><tr><td>AL096865</td><td>RUNX2</td><td>(-2.4)</td><td>-</td><td>(2.4)</td></tr><tr><td>NM_006350</td><td>FST</td><td>-</td><td>-</td><td>(2.4)</td></tr><tr><td colspan="5">Hedgehog signalling pathway (HH)</td></tr><tr><td>NM_001892</td><td>CSNK1A1</td><td>-</td><td>(4.5)</td><td>-</td></tr><tr><td>NM_016004</td><td>IFT52</td><td>-</td><td>(2.5)</td><td>-</td></tr><tr><td>NM_005870</td><td>SAP18</td><td>(-5.3)</td><td>(-3.7)</td><td>(6.2)</td></tr></table> |
b4d2f7ef975615a9959e559fb5d017941f5fda45d1999765c7761a0e8aa7c22b.png | simple | <table><tr><td> </td><td><i>β</i></td><td>SE</td><td>OR</td><td>CI</td><td><i>P</i></td></tr><tr><td>Age (>1–7 Years)</td><td>0.489</td><td>0.294</td><td>1.63</td><td>0.916–2.903</td><td>0.097</td></tr><tr><td>Cats per household (>1)</td><td>−0.714</td><td>0.292</td><td>0.49</td><td>0.276–0.869</td><td>0.015</td></tr><tr><td>Body condition (Regular-bad)</td><td>0.928</td><td>0.338</td><td>2.53</td><td>1.306–4.904</td><td>0.006</td></tr></table> |
d5869b2869ace91372b384fa8a8ad2069021f1aca77935c6a0faa3f6c61cf923.png | complex | <table><tr><td>Patient Group</td><td colspan="2">P53 expression</td><td>χ<sup>2</sup></td><td>P value</td></tr><tr><td>(No. of cases)</td><td>(+)</td><td>(-)</td><td></td><td></td></tr><tr><td>Grade I (14)</td><td>0</td><td>14</td><td>6.568</td><td>0.037</td></tr><tr><td>Grade II (10)</td><td>2</td><td>8</td><td></td><td></td></tr><tr><td>Grade III (16)</td><td>6</td><td>10</td><td></td><td></td></tr></table> |
3e23c6769b1ae162005e956f944dcd24659177a365ae59dce6e4adaa156bd112.png | simple | <table><tr><td> </td><td>Arlee</td><td>Clearwater</td><td>Skamania</td><td>Swanson</td><td>Whale rock</td></tr><tr><td>Arlee</td><td>-</td><td>2292</td><td>1460</td><td>1180</td><td>1628</td></tr><tr><td>Clearwater</td><td>(3300)</td><td>-</td><td>1425</td><td>1283</td><td>2412</td></tr><tr><td>Skamania</td><td>(2109)</td><td>(2156)</td><td>-</td><td>792</td><td>1486</td></tr><tr><td>Swanson</td><td>(1722)</td><td>(1846)</td><td>(1197)</td><td>-</td><td>1182</td></tr><tr><td>Whale Rock</td><td>(2359)</td><td>(3451)</td><td>(2191)</td><td>(1716)</td><td>-</td></tr></table> |
311233be241b6082ddf3153305e7d3ad2c344c3654ec4e2b0b0fe0448bbd75a5.png | simple | <table><tr><td>Molecule</td><td>FIC<sup>a</sup></td></tr><tr><td>Caspofungin</td><td>0.27 (0.10)</td></tr><tr><td>CP29</td><td>0.54 (0.07)</td></tr><tr><td>DmAMP1</td><td>0.19 (0.00)</td></tr><tr><td>Fluconazole</td><td>1.00 (0.00)</td></tr><tr><td>HbD2</td><td>0.71 (0.31)</td></tr><tr><td>HST5</td><td>0.67 (0.07)</td></tr><tr><td>LL37</td><td>0.49 (0.16)</td></tr><tr><td>NaD2</td><td>0.69 (0.11)</td></tr></table> |
49a2747f7dba8d8bcfa8ecbe4a3f26de934ffc224c7fe3b419d95bd8ec585ba3.png | simple | <table><tr><td>Strain (No. of Strains)</td><td><sup>a</sup> FOX</td><td><sup>a</sup> E</td><td><sup>a</sup> DA</td><td><sup>a</sup> T</td><td><sup>a</sup> C</td><td><sup>a</sup> CIP</td><td><sup>a</sup> CN</td><td><sup>a</sup> RIF</td><td><sup>a</sup> LNZ</td><td><sup>a</sup> SXT</td></tr><tr><td><i>S. epidermidis</i> (32)</td><td>25/78.1</td><td>18/56.3</td><td>26/81.3</td><td>25/78.1</td><td>32/100</td><td>32/100</td><td>31/96.9</td><td>32/100</td><td>31/96.9</td><td>23/71.9</td></tr><tr><td><i>S. haemolyticus</i> (31)</td><td>26/83.9</td><td>14/45.2</td><td>19/61.3</td><td>26/83.9</td><td>25/80.6</td><td>27/87.1</td><td>28/90.3</td><td>31/100</td><td>31/100</td><td>18/58.1</td></tr><tr><td><i>S. capitis subsp. capitis</i> (21)</td><td>17/81</td><td>9/42.9</td><td>15/71.4</td><td>19/90.5</td><td>21/100</td><td>10/47.6</td><td>10/41.6</td><td>19/90.5</td><td>21/100</td><td>17/81</td></tr><tr><td><i>S. hominis</i> (11)</td><td>10/90.9</td><td>4/36.4</td><td>9/81.8</td><td>6/54.5</td><td>9/81.8</td><td>11/100</td><td>11/100</td><td>11/100</td><td>11/100</td><td>8/72.7</td></tr><tr><td><i>S. cohnii subsp. cohnii</i> (9)</td><td>7/77.8</td><td>5/55.6</td><td>5/55.6</td><td>5/55.6</td><td>9/100</td><td>9/100</td><td>9/100</td><td>9/100</td><td>9/100</td><td>5/55.6</td></tr><tr><td><i>S. saprophyticus</i> (5)</td><td>5/100</td><td>1/20</td><td>4/80</td><td>5/100</td><td>5/100</td><td>5/100</td><td>5/100</td><td>5/100</td><td>5/100</td><td>3/60</td></tr><tr><td><i>S. kloosii</i> (4)</td><td>4/100</td><td>2/50</td><td>3/75</td><td>1/25</td><td>3/75</td><td>4/100</td><td>4/100</td><td>4/100</td><td>4/100</td><td>4/100</td></tr><tr><td><i>S. warneri</i> (4)</td><td>3/75</td><td>1/25</td><td>1/25</td><td>3/75</td><td>3/75</td><td>4/100</td><td>4/100</td><td>4/100</td><td>4/100</td><td>3/75</td></tr><tr><td><i>S. cohnii subsp. urealyticum</i> (2)</td><td>2/100</td><td>0/0</td><td>1/50</td><td>1/50</td><td>2/100</td><td>2/100</td><td>2/100</td><td>2/100</td><td>2/100</td><td>1/50</td></tr><tr><td><i>S. lugdunensis</i> (1)</td><td>1/100</td><td>1/100</td><td>1/100</td><td>1/100</td><td>1/100</td><td>1/100</td><td>1/100</td><td>1/100</td><td>1/100</td><td>1/100</td></tr><tr><td><i>S. hyicus</i> (1)</td><td>1/100</td><td>1/100</td><td>1/100</td><td>1/100</td><td>1/100</td><td>1/100</td><td>1/100</td><td>1/100</td><td>1/100</td><td>0/0</td></tr><tr><td><i>S. chromogenes</i> (1)</td><td>1/100</td><td>0/0</td><td>1/100</td><td>0/0</td><td>1/100</td><td>1/100</td><td>1/100</td><td>1/100</td><td>1/100</td><td>1/100</td></tr><tr><td>Total (122)/%</td><td>10/83.6</td><td>56/45.9</td><td>86/70.5</td><td>93/76.2</td><td>112/91.8</td><td>107/87.7</td><td>107/87.7</td><td>120/98.4</td><td>121/99.2</td><td>84/68.9</td></tr></table> |
24d7b2d335f9c748462bc3526dcb0d36e4a51a426cb2764e010843d5585816b5.png | complex | <table><tr><td></td><td></td><td colspan="3">OR (95% CI)</td></tr><tr><td>Exposure</td><td><i>n</i> (cases/total)</td><td>Unadjusted model 1</td><td>Adjusted model 2b</td><td>Adjusted model 3c</td></tr><tr><td colspan="5">Periconceptional CO</td></tr><tr><td colspan="5">Categorized by quartiles (ppm)</td></tr><tr><td> 0.09–0.59</td><td>21/878</td><td>1.00 (Referent)</td><td>1.00 (Referent)</td><td>1.00 (Referent)</td></tr><tr><td> 0.60–0.80</td><td>27/877</td><td>1.30 (0.73–2.31)</td><td>1.44 (0.79–2.62)</td><td>1.04 (0.55–1.96)</td></tr><tr><td> 0.81–1.02</td><td>30/877</td><td>1.45 (0.82–2.54)</td><td>1.65 (0.91–3.00)</td><td>0.86 (0.42–1.75)</td></tr><tr><td> 1.03–3.73</td><td>39/877</td><td>1.90 (1.11–3.26)</td><td>2.08 (1.16–3.72)</td><td>0.75 (0.42–1.64)</td></tr><tr><td> Per 0.1-ppm increase</td><td></td><td>1.07 (1.02–1.12)</td><td>1.07 (1.02–1.13)</td><td>0.98 (0.91–1.06)</td></tr><tr><td colspan="5">Periconceptional PM<sub>2.5</sub></td></tr><tr><td colspan="5">Categorized by quartiles (μg/m<sup>3</sup>)</td></tr><tr><td> 5.9–8.7</td><td>31/878</td><td>1.00 (Referent)</td><td>1.00 (Referent)</td><td>1.00 (Referent)</td></tr><tr><td> 8.8–10.1</td><td>24/877</td><td>0.77 (0.45–1.32)</td><td>0.79 (0.45–1.39)</td><td>0.78 (0.43–1.41)</td></tr><tr><td> 10.2–11.4</td><td>32/882</td><td>1.03 (0.62–1.70)</td><td>1.50 (0.80–2.81)</td><td>1.38 (0.71–2.70)</td></tr><tr><td> 11.5–15.1</td><td>30/872</td><td>0.97 (0.58–1.62)</td><td>1.63 (0.79–3.38)</td><td>1.41 (0.63–3.18)</td></tr><tr><td> Per 0.5-μg/m<sup>3</sup> increase</td><td></td><td>1.00 (0.94–1.05)</td><td>1.04 (0.95–1.12)</td><td>1.02 (0.93–1.12)</td></tr></table> |
c6174a886a26058fd611b2777ad984686ebb9bc5ee5f0c359e0240f24b68a34f.png | simple | <table><tr><td>Plant Age (Weeks)</td><td>Free PAA pmol (g FW)<sup>−</sup><sup>1</sup></td><td>Free IAA pmol (g FW)<sup>−</sup><sup>1</sup></td></tr><tr><td>Two weeks</td><td>98 ± 6.4</td><td>35 ± 2.7</td></tr><tr><td>Six weeks</td><td>23 ± 2</td><td>15 ± 1</td></tr></table> |
ae9b5a91850833b5e74795d4d59f1613082983d3aa48d12708b7b35842c442e9.png | complex | <table><tr><td colspan="3">Misclassification cost setting 5:1, post-pruning confidence 1%</td></tr><tr><td></td><td colspan="2">Classified as</td></tr><tr><td>Observed</td><td>SN</td><td>Non-SN</td></tr><tr><td>SN</td><td>0</td><td>34</td></tr><tr><td>Non-SN</td><td>0</td><td>815</td></tr><tr><td colspan="3">Misclassification cost setting 10:1, post-pruning confidence 1%</td></tr><tr><td></td><td colspan="2">Classified as</td></tr><tr><td>Observed</td><td>SN</td><td>Non-SN</td></tr><tr><td>SN</td><td>8</td><td>26</td></tr><tr><td>Non-SN</td><td>66</td><td>749</td></tr><tr><td colspan="3">Misclassification cost setting 25:1, post-pruning confidence 50%</td></tr><tr><td></td><td colspan="2">Classified as</td></tr><tr><td>Observed</td><td>SN</td><td>Non-SN</td></tr><tr><td>SN</td><td>31</td><td>3</td></tr><tr><td>Non-SN</td><td>18</td><td>797</td></tr></table> |
0c08ce8874e24ad0ea31be789ebaa93909249e84f233af4a65aa080b00b25356.png | simple | <table><tr><td>Reference</td><td>Type of study</td><td>Subjects/number of studies</td><td>Results</td></tr><tr><td>Knutson et al. (72)</td><td>Cohort study and longitudinal, blood pressure and actigraphic sleep measured at 5-year intervals</td><td>578 AA and White</td><td>Reduced sleep predicted higher BP and adverse change in BP; sleep duration appeared to mediate racial differences in diastolic BP</td></tr><tr><td>Knutson (54)</td><td>National surveys, self-report</td><td>8 surveys conducted over 31 years</td><td>AAs consistently more likely to report short sleep duration than any other racial group</td></tr><tr><td>Vishnu et al. (73)</td><td>Cross-sectional survey, self-report</td><td>369,217 multi-ethnic US subjects</td><td>Strongest correlation between insufficient sleep and CHD found in AAs</td></tr><tr><td>Ruiters et al. (66)</td><td>Meta-analysis, variable methods including subjective and objective measures of sleep</td><td>14 studies</td><td>AAs had poorer sleep continuity and duration, less slow wave sleep, and a greater proportion of stage 2 sleep</td></tr><tr><td>Jean-Louis et al. (74)</td><td>National Health Interview Survey, 1977–2009, cross-sectional, face to face interviews</td><td>All ethnicities surveyed but restricted to Black and White participants</td><td>Among Black, very short sleepers 76% increased risk of overweight and 81% increased risk of obese</td></tr><tr><td>Halder et al. (68)</td><td>Cohort study using PSQI and in home polysomnography, correlation with % African genetic ancestry</td><td>70 AA and 101 European-American</td><td>% African ancestry correlated with lower percentage slow wave sleep but not sleep duration or efficiency</td></tr><tr><td>Curtis et al. (63)</td><td>Cross-sectional, actigraphic sleep</td><td>426 Midwestern US adults with oversampling of AAs</td><td>AA obtained less sleep and had lower sleep efficiency. Sleep duration predicted 41% of cardiometabolic risk factor variance</td></tr><tr><td>Johnson et al. (67)</td><td>Cross-sectional analysis, self-report</td><td>5,301 AAs in the Jackson Heart Study</td><td>54% reported <6 h sleep, 5% >9 h sleep. Social and environmental characteristics associated with sleep duration</td></tr><tr><td>Riestra et al. (70)</td><td>Cross-sectional analysis</td><td>2,962 AA participants</td><td>A SNP in the CLOCK gene associated with sleep duration after multifactorial adjustments</td></tr></table> |
a4cdd4a7b75ff7c6fa1d23a63bd7f66f6cc88d3152b506d09ffb8858120f9607.png | simple | <table><tr><td> </td><td>Interest learning MBP (%)</td><td>Interest in participating in study of MBP during MHD (%)</td></tr><tr><td>Total (<i>n</i> = 89)</td><td>70</td><td>74</td></tr><tr><td>Age (years)</td><td> </td><td> </td></tr><tr><td> 18–34</td><td>100</td><td>100</td></tr><tr><td> 35–49</td><td>54</td><td>69</td></tr><tr><td> 50–64</td><td>71</td><td>74</td></tr><tr><td> 65–79</td><td>78</td><td>78</td></tr><tr><td> ≥80 </td><td>46</td><td>46</td></tr><tr><td>Gender </td><td> </td><td> </td></tr><tr><td> Female</td><td>74</td><td>74</td></tr><tr><td> Males</td><td>66</td><td>75</td></tr><tr><td>Race</td><td> </td><td> </td></tr><tr><td> White</td><td>54</td><td>65</td></tr><tr><td> Black</td><td>76</td><td>74</td></tr><tr><td> Other</td><td>71</td><td>100</td></tr><tr><td>Dialysis Vintage (years)</td><td> </td><td> </td></tr><tr><td> <1</td><td>75</td><td>79</td></tr><tr><td> 1–4</td><td>68</td><td>74</td></tr><tr><td> 5–9</td><td>78</td><td>89</td></tr><tr><td> ≥10</td><td>50</td><td>50</td></tr><tr><td>Ever used CAM use</td><td> </td><td> </td></tr><tr><td> No</td><td>62</td><td>54</td></tr><tr><td> Yes</td><td>74</td><td>87</td></tr></table> |
1f0c8e2133f4294852f86845f6f71b12f221f3485252fa98bb9e21b76b81fffa.png | simple | <table><tr><td>Processing procedure</td><td>P(%)</td><td>R(%)</td><td>F(%)</td></tr><tr><td>(1): only candidate drugs replaced</td><td>75.9</td><td>68.7</td><td>71.5</td></tr><tr><td>(2): basic processing</td><td>77.5</td><td>72.3</td><td>74.8</td></tr><tr><td>(3): (2) + Following anaphora</td><td>76.9</td><td>76.5</td><td>76.7</td></tr><tr><td>(4): (3) + Pruned Sentences</td><td>78.4</td><td>76.2</td><td>77.3</td></tr></table> |
e9a2c6a6d2279703a5db99881550ef6af031ba6e8a7d3240de3f056d60cef1d4.png | simple | <table><tr><td></td><td>ASA Respondents (<i>n </i>= 209)</td><td>ESA Respondents (<i>n </i>= 165)</td></tr><tr><td>Answer Options</td><td>Response Percent</td><td>Response Percent</td></tr><tr><td>Blood pressure</td><td>88.5%</td><td>77.6%</td></tr><tr><td>Urine output</td><td>83.3%</td><td>77.0%</td></tr><tr><td>Clinical experience</td><td>77.5%</td><td>64.8%</td></tr><tr><td>Central venous pressure</td><td>70.8%</td><td>64.2%</td></tr><tr><td>Cardiac output</td><td>49.3%</td><td>53.3%</td></tr><tr><td>Pulse Pressure Variation or Systolic Pressure Variation</td><td>45.0%</td><td>55.8%</td></tr><tr><td>Transesophageal echocardiography</td><td>43.5%</td><td>28.5%</td></tr><tr><td>Pulmonary capillary wedge pressure</td><td>38.8%</td><td>24.2%</td></tr><tr><td>Plethysmographic Waveform Variation</td><td>25.4%</td><td>25.5%</td></tr><tr><td>Stroke Volume Variation</td><td>19.1%</td><td>36.4%</td></tr><tr><td>Mixed venous saturation (ScvO2)</td><td>18.7%</td><td>21.8%</td></tr><tr><td>Global end diastolic volume</td><td>10.5%</td><td>17.0%</td></tr><tr><td>Central venous saturation (SvO2)</td><td>10.0%</td><td>34.5%</td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.